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ABSTRACT
The two cellular components of B cell memory are antibody (Ab)-secreting cells (ASCs) and
memory B cells (BMem). BMem are quiescent cells that respond to “recall” antigen and contribute
substantially to vaccine effectiveness. The rational evaluation of vaccination strategies is
dependent on quantitative information on the state of B cell memory. Despite the importance of
BMem in resistance to infection, there is little information on the nature of BMem populations
generated by influenza infection or vaccination. The major goal of this dissertation was a
comprehensive quantitative analysis of the frequency and distribution of influenza-specific BMem
generated by influenza infection of the respiratory tract, or by vaccination with inactivated virus.
To achieve this, a prerequisite was the development of a sensitive and reproducible
limiting dilution assay (LDA) for determining influenza-specific BMem frequencies. The results in
Chapter 2 demonstrated that a strategy utilizing BPL-inactivated virus particles was effective for
the in vitro activation of virus-specific BMem. This strategy selectively activates virus-specific
BMem and, importantly, achieves this without a requirement for CD4+ T cell associated factors.
Using this strategy, the frequency of Influenza specific BMem in different anatomical sites
was measured and we also tested three different forms of influenza virus immunization strategy;
(i) intranasal (i.n.) infection, (ii) i.n. vaccination, (iii) intramuscular (i.m.) vaccination. The
results in Chapter III, IV showed that following different forms of immunization, BMem dispersed
broadly to organized lymphoid tissues throughout the body, and a population of ASCs was
established in the bone marrow. ASC and BMem frequencies in these locations reflected the
magnitude of the primary B cell response to the form of immunization. Thus, the frequencies
were higher following i.n. infection. Interestingly, the state of B cell memory in the lung was
v

profoundly influenced by the form of immunization. The lung was a preferential site of BMem
localization after i.n. infection. However, this was not the case after i.m. immunization when
BMem frequencies in the lung were considerably lower than in other sites. Our findings point to an
effect of influenza infection on the lung environment that profoundly influences ASC and BMem
trafficking to this site.
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Chapter 1
Background and Overview
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Introduction
Influenza is a contagious respiratory viral illness of global importance and is a significant cause
of morbidity and mortality annually. Four or five pandemics of influenza occurred during
the last century with intervals of 9-39 years. By far the worst was the pandemic of 1918 – 1920.
Over a 10-month period, this "Spanish flu" killed an estimated 40-50 million people worldwide
with many of the deaths occurring in young, previously healthy adults.
When symptomatic, influenza typically produces an acute febrile illness characterized by
cough, headache and myalgia. The majority of morbidity and mortality occurs in the elderly with
underlying chronic cardiorespiratory disease or diabetes mellitus, particularly those in residential
care. Complications of acute influenza include viral and secondary bacterial pneumonias,
exacerbations of pre-existing cardiopulmonary disease and, in children and infants, croup, otitis
media, bronchiolitis and febrile convulsions (Glezen 1982; Nicholson 1992).
Each year, circulating influenza viruses are responsible for approximately 40,000 deaths
and up to 150,000 hospitalizations in the United States (Thompson, Shay et al. 2003; Harper,
Fukuda et al. 2005). On top of this are growing concerns of a developing influenza pandemic.
Avian influenza viruses of the H5N1 subtype with potential for high virulence in humans
continue to expand their distribution from initial sites of emergence in Southeast Asia. Mutations
that enable efficient spread of H5N1 viruses within an immunologically naïve human population
may occur and serve as a pandemic trigger. Clearly, there is a strong need to continue to develop
and improve strategies to combat influenza.
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The challenge of antigenic change in influenza viruses
Influenza viruses have segmented genomes and show great antigenic diversity. Of the
three types of influenza viruses-A, B, and C-only types A and B cause widespread outbreaks.
Influenza A viruses are classified into subtypes based on antigenic differences between their two
surface glycoproteins, haemagglutinin and neuraminidase. 15 haemagglutinin subtypes (H1–H15)
and nine neuraminidase subtypes (N1–N9) have been identified for influenza A viruses.
Viruses of all haemagglutinin and neuraminidase subtypes have been recovered from aquatic
birds, but only three haemagglutinin subtypes (H1, H2, and H3) and two neuraminidase subtypes
(N1 and N2) have established stable lineages in the human population since 1918. Only one
subtype of haemagglutinin and one of neuraminidase are recognised for influenza B viruses.
Haemagglutinin facilitates entry of the virus into host cells through its attachment to sialic-acid
receptors. It is the major antigenic determinant of type A and B viruses to which neutralizing
antibodies (Abs) are directed and the crucial component of current influenza vaccines. Five Abcombining sites have been mapped on the HA of H3 subtype human influenza A viruses (Wilson
and Cox 1990); however, less is known about HAs of avian influenza A subtypes.
An important function of neuraminidase, the second major antigenic determinant, is to
catalyze the cleavage of glycosidic linkages to sialic acid, thereby assisting in the release of
progeny virions from infected cells. Accordingly, neuraminidase has become an important target
for antiviral activity. The M2 ion channel of influenza A, which is blocked by the antiviral drug
amantadine, regulates the internal pH of the virus, which is crucial during early viral replication.
Influenza vaccination is the primary method for preventing influenza and its severe
complications. However, the biology of influenza virus presents a major challenge to effective
3

vaccination. Influenza viruses utilize two mechanisms, referred to as antigenic drift and antigenic
shift, to evade the human immune response. Point mutations that occur during viral replications
continuously generate antigenic change (antigenic drift), especially in the surface hemagglutinin
(HA) and neuraminidase (NA) glycoproteins of influenza A viruses. These surface molecules are
the basis for categorizing influenza A viruses into subtypes (e.g. H3N2, H1N1). Abs induced by
vaccination with one antigenic form may confer profound protection against infection with the
homologous virus. However, the protection may be substantially less against a “drifted” variant,
even though the viral subtype remains the same. As a general rule, Abs raised against one
subtype provide little, if any, protection against a completely novel subtype. This feature enables
the virus to evade immune recognition, leading to repeated outbreaks during interpandemic years.
Antigenic shift is a rare but occurs with the emergence of a “new”, potentially pandemic,
influenza A virus that possesses a novel HA alone or with a novel NA. The novel HA and NA
genes in pandemic influenza viruses are derived from the reservoir of avian influenza viruses in
nature (Reid, Fanning et al. 2004; Reid, Taubenberger et al. 2004). The new virus is antigenically
distinct from circulating human influenza viruses and Abs towards the previously circulation
subtype do not cross-react with the new subtype.
A major goal of influenza vaccination is to generate broad protection against variants
within a subtype (heterovariant protection) and, optimally, against a range of different subtypes
(heterosubtypic protection).
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Human influenza vaccines
Since the 1940s, inactivated influenza vaccines have been developed for the control of
annual influenza epidemics (Hilleman 2000). Two forms of influenza vaccine are currently
licensed for use in humans in the United States: (i) an inactivated vaccine administered
intramuscularly (i.m.), and (ii) a live attenuated intranasal (i.n.) vaccine. Both vaccine forms are
prepared from the same set of three viruses, two influenza A viruses and an influenza B virus,
that are predicted to match the predominant circulating viruses in the next flu season.
Three types of inactivated influenza vaccine are currently recommended by WHO; whole
virus, detergent-treated split product and purified surface antigen. All commercially produced
influenza vaccines are grown in eggs and inactivated by either formaldehyde or β-propiolactone
(Davenport, Hennessy et al. 1964; Bachmayer 1975; Brady and Furminger 1976; Brady and
Furminger 1976). Early whole virion inactivated vaccines were associated with frequent local
and systemic adverse effects in young children(Davenport, Hennessy et al. 1964). Accordingly,
whole virion influenza vaccines are little used and are unlicensed in many countries. At the
present time, inactivated split-virus and subunit influenza vaccines receive more widespread use,
and it is the only vaccine form approved for administration to children aged <5 years and adults
aged ≥50 years.
Intranasal delivery of live influenza vaccines offers the advantage of mimicking natural
infection, thereby providing a broader immunological response and more durable protection than
with inactivated vaccines (Murphy and Clements 1989; Murphy and Coelingh 2002). However,
in the United States, live attenuated virus vaccine is only approved for the age group of 5-49,
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thus excluding two major high-risk groups, infants and the elderly, in addition to
immunocompromised patients and pregnant woman.
.

A key determinant of the efficacy of both vaccine forms is the ability to induce strong B

cell responses against the component viruses. The inactivated vaccine is essentially a “B cell
vaccine”. Protective efficacy of the live vaccine is also ascribed primarily to the induction of
virus-specific Abs (Murphy and Coelingh 2002), although replicating virus also facilitates
priming of virus-specific cytotoxic T cells (Gorse, Campbell et al. 1995). The key point is that B
cell responses are of central importance in vaccine-induced protection against influenza. More
precisely, it is the vaccine-induced state of B cell memory that is all important.

Immune responses and memory in a mouse model of influenza infection
Influenza virus infection of the respiratory tract in mice is a well-characterized model that
has many features in common with human influenza infection. This model has been used
extensively to study the immune response to infection and vaccination, and to identify the
components of the adaptive immune response that are most effective in mediating virus
clearance and providing protection against re-infection (Doherty, Topham et al. 1997; Gerhard,
Mozdzanowska et al. 1997).
Influenza viruses infect epithelial cells of the upper respiratory tract and bronchi, as well
as mononuclear cells (Ronni, Sareneva et al. 1995). Intranasal administration of the A/HKx31
(H3N2) influenza A virus to C57BI/6J (B6) mice leads to the development of primary viral
pneumonia. In the B6 model, virus is cleared 10 days after infection, with no indication of
6

persistent antigen or viral RNA (Allan, Tabi et al. 1990). Recovery or prevention of influenza
relies on both innate and adaptive response in the immunologically intact mouse. This has been
evidenced by increased mortality or delayed recovery of mice that have a defective type I
interferon response system (Lindenmann, Lane et al. 1963; Haller, Arnheiter et al. 1979; GarciaSastre, Durbin et al. 1998) or complement system (Hicks, Ennis et al. 1978; Kopf, Abel et al.
2002) or are deficient in major histocompatibility complex class I (MHC-I)-restricted CD8+ T
(Bender, Croghan et al. 1992) or B cells (Gerhard, Mozdzanowska et al. 1997; Graham and
Braciale 1997; Topham and Doherty 1998; Baumgarth, Herman et al. 2000; Kopf, Brombacher
et al. 2002; Webby, Andreansky et al. 2003).

Innate response to influenza virus infection
Respiratory epithelial cells are the primary targets for influenza A virus infection. This
localized pathology reflects that the production of new virus requires cleavage of the surface HA
molecule by an enzyme restricted in distribution to the superficial epithelial layer of the
respiratory tract (Walker, Sakaguchi et al. 1992; Rott, Klenk et al. 1995). Following influenza
infection, respiratory epithelial cells produce large amounts of virus which can then infect
alveolar macrophages and immature respiratory dentritic cells (RDC). In addition, cell
necrosis/apoptosis triggers innate immune responses and local production of cytokines such as
type I interferon, TNF-α, IL-12,

IL-1 and chemokines such as monocyte chemoattractant

protein-1 (MCP-1), regulated on activation, normal T-cell expressed and secreted (RANTES),
MIP-1α/β, interferon induced protein (IP-10) (Matsukura, Kokubu et al. 1996; Sprenger, Meyer
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et al. 1996; Adachi, Matsukura et al. 1997; Bussfeld, Kaufmann et al. 1998; Dawson, Beck et al.
2000). These proinflammatory cytokines and chemokines produced by infected cells cause the
extravasation of small numbers of blood-derived neutrophils initially, followed by larger
numbers of blood monocytes/macrophages from the peripheral blood across the endo-epithelial
barrier into infected lung tissue within the first 3 days after influenza A virus infection (Table 1.)
(Ada and Jones 1986; La Gruta, Kedzierska et al. 2007). During this period, viral replication
continues in the epithelial cells and infection spreads to the recruited macrophages (Fujisawa,
Tsuru et al. 1987; Hofmann, Sprenger et al. 1997). These processes alone are not able to clear the
virus from the lung. By day 7, CD8+ cytotoxic T cells (CTLs) from mediastinal lymph nodes
begin to accumulate in the infected lung and the efficient process of T cell mediated viral
clearance begins (Bender and Small 1992; Shaw, Arden et al. 1992).

Adaptive response to influenza virus infection
The adaptive response to influenza virus is mediated by neutralizing antibody producing
B cells, and CD4+ helper T cells, and CD8+ cytotoxic T lymphocytes (CTL) that kill infected
cells (Doherty, Topham et al. 1997; Gerhard, Mozdzanowska et al. 1997; Topham, Tripp et al.
1997; Doherty and Christensen 2000; Wong and Pamer 2003; Brown, Roman et al. 2004). To
initiate anti-influenza adaptive immune response, Antigen presenting cells (macrophages and
DCs) are essential. Influenza infection via TLR3, TLR7/8 results in DC activation, maturation
and migration of the DC from the respiratory tract through the afferent lymphatics to draining
lymph nodes (Figure 1). DC then present viral antigen to virus-specific naïve T cells which
8

triggers T cell activation/differentiation. influenza-specific naïve T cells can differentiate into
Th1 and Th2. Th1 cells secrete IFN-γ, IL-2 and help IgG2a/c Ab production, while Th2 cell
secrete IL-4 and IL-5 and help IgA, IgG1 Ab production (Ada and Jones 1986) in the germinal
center of the lymph node. Each antibody isotype produced during the immune response is
known to have specific functions (Table 2.). Typically, influenza infection leads to a strong Th1
type of response followed by dominating IgG2a/c production (Sangster, Riberdy et al. 2003).
Th1 cells are also essential in the generation and maintenance of CD8+ T cell memory by
secreting IL-2, though in the primary response, CD4+ T cells are not required for expansion or
development of functional CD8+ CTL (Riberdy, Christensen et al. 2000; Thomas, Keating et al.
2006).
The consequences of the immune response in the lymph node, production of influenzaspecific Abs contributing to viral neutralization due to binding with viral antigen. In addition,
differentiated effector T cells can leave the draining lymph nodes through the efferent lymphatics
and circulatory system and then localize to infected lung (Legge and Braciale 2003; Langlois and
Legge 2007).

Characteristics of B cell memory
Studies of the mouse model have established that influenza infection elicits a vigorous
primary B cell response and extensive anti-viral Ab production that contributes substantially to
virus clearance and recovery (Gerhard, Mozdzanowska et al. 1997). A consequence of this B cell
response is a state of B cell memory that provides profound long-term protection against reinfection with the same virus or an antigenically related virus. Two components of B cell
9

memory can be identified: (i) plasma cells, and (ii) BMem. Long-lived plasma cells (Slifka, Antia
et al. 1998) secreting high affinity anti-viral Abs are found predominantly in the bone marrow
(Hyland, Sangster et al. 1994; Sangster, Hyland et al. 1995; Slifka, Matloubian et al. 1995) and at
mucosal surfaces (Liang, Hyland et al. 2001). IgA Abs produced by sub-mucosal plasma cells,
and serum IgG derived from the bone marrow plasma cell population, provide anti-viral activity
in the upper and lower respiratory tract, respectively. BMem are also long-lived (Schittek and
Rajewsky 1990) but, unlike plasma cells, they are quiescent, non-Ab-secreting cells that
distribute to lymphoid tissues throughout the body (Bachmann, Kundig et al. 1994; Slifka and
Ahmed 1996). If a previously encountered virus manages to escape the barrier of pre-existing
Abs and re-establishes an infection, BMem are stimulated to produce a secondary anti-viral Ab
response that is even more rapid and effective than the primary response (Sangster, Smith et al.
1995). Thus, a BMem response functions to greatly curtail the duration and severity of infection.

Characteristics of memory B cells
The BMem generated in germinal centers as part of T cell-dependent B cell responses
(McHeyzer-Williams, Driver et al. 2001) typically express an isotype-switched surface Ig
receptor (IgG, IgA, or IgE) with high Ag-binding affinity, and also the mature B cell markers
CD19 and B220 (Ridderstad and Tarlinton 1998). Recent evidence for a CD19- B220- BMem
population (McHeyzer-Williams, Driver et al. 2001) is controversial (Bell and Gray 2003). It is
generally thought that BMem recirculate and establish similar frequencies in lymphoid tissues
throughout the body (Bachmann, Kundig et al. 1994). Although there is some evidence that BMem
10

may preferentially localize at mucosal surfaces (Liu, Barthelemy et al. 1995), this has not been
fully investigated and may relate to the Ab isotype expressed and the route of immunization
(Moser and Offit 2001).
BMem are quiescent, non-Ab-producing cells. It is only upon activation that BMem divide
and differentiate into plasma cells producing high affinity Abs. Typically, this process is initiated
in vivo when BMem are exposed to specific Ag in the presence of CD4+ T cell help (Vieira and
Rajewsky 1990). BMem are strong Ag-presenting cells. High affinity surface Ig receptors on BMem
facilitate Ag capture for presentation to specific CD4+ T cells, and the constitutive expression of
the costimulatory molecules CD80 and CD86 by BMem promotes cognate T-B interaction (Liu,
Barthelemy et al. 1995). In vitro studies have demonstrated that BMem, but not naïve B cells,
generate substantial numbers of plasma cells when stimulated with T cell-derived signals such as
CD40 ligand, IL-2, and IL-10. The presence of specific Ag was not a requirement (Bernasconi,
Traggiai et al. 2002; Tangye, Avery et al. 2003). Indeed, non-specific methods of BMem
activation have been used as a basis for assays to determine Ag-specific BMem frequencies
(Nanan, Heinrich et al. 2001), but the sensitivity of such an approach remains unclear. It has
recently been suggested that “bystander” BMem may differentiate into plasma cells in response to
non-specific signals from CD4+ T cells activated in the course of normal in vivo immune
responses (Bernasconi, Traggiai et al. 2002).
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Characteristics of Plasma cells
Long-lived antibody-secreting B cells can also be considered part of the memory B cell
compartment. The long-lived plasma cells (LLPC) are terminally differentiated cells that
continually produce high-affinity antibody and survive for the life of the mouse in the absence of
antigen and cell division (Manz, Thiel et al. 1997; Manz, Lohning et al. 1998; Slifka, Antia et al.
1998). These nondividing cells differ from BMem in many respects. For instance, plasma cells
down-regulate surface expression of many typical B cell markers, including MHC class II and
surface Ig (Abney, Cooper et al. 1978; Halper, Fu et al. 1978). These changes indicate that unlike
memory B cells, mature plasma cells are unlikely to function as antigen presenting cells. LLPC
preferentially homes to the bone marrow for their survival. The survival factors could include
CXCL12, IL-6, B cell-activation factor (BAFF), a proliferation inducing ligand (APRIL), and
CD44. Recently, the plasma-cell marker CD138 (also known as syndecan-1) was identified as a
receptor for APRIL that is involved in the homing of plasma cells to the bone marrow. Inhibition
of BAFF and APRIL, both of which are lignads for the B cell maturation antigen (BCMA)
receptor, which is expressed by plasma cells (O'Connor, Raman et al. 2004), but not BAFF alone,
was found to prevent the survival and/or the migration of newly formed plasma cells to the bone
marrow (Ingold, Zumsteg et al. 2005). In addition to the bone marrow, survival factors for LLPC
are also expressed in inflamed tissues (Baggiolini 1998; Cassese, Lindenau et al. 2001;
Muehlinghaus, Cigliano et al. 2005). The presence of interferon-γ (IFN-γ), a hallmark of
inflamed tissue, increase both the expression of CXCR3 on B cells differentiating into
plasmablasts and the expression of CXCR3 ligands by cells in the inflamed tissue, indicating that
IFN-γ might be particularly important for the attraction of plasmablasts to inflamed tissues.
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When migratory plasmablasts reach the inflamed tissue, they become resident long-lived plasma
cells, which do not have migratory capacity. It is not clear, however, whether resident plasma
cell population in inflamed tissues contributes to serum antibody concentration or provides local
protection as the humoral memory. It also remains to be determined whether the maintenance of
antibody concentrations that are observed following a primary immune response is due to long
lived plasma cells generated from activated naïve B cells or whether it results from reactivation
of specific BMem that were generated in the primary immune response (Blink, Light et al. 2005;
Dorner and Radbruch 2005).

Quantitation of memory B cells
Despite the important contribution that a BMem response makes to resistance to infection,
there have been few quantitative studies of the BMem pool induced by virus infection. Many
studies of B cell memory have focused on responses to simple haptens or fluorochromes, since
these molecules can be utilized in cell staining strategies to identify BMem expressing specific,
high affinity receptors (Schittek and Rajewsky 1990; Ridderstad and Tarlinton 1998; Shimoda,
Nakamura et al. 2001; Bell and Gray 2003). However, such an approach cannot be applied to
virus-specific B cells which generally bind poorly defined conformational epitopes. Virusspecific BMem can be identified by the transfer of immune cells to a recipient animal followed by
virus challenge (Bachmann, Kundig et al. 1994), but this approach is time consuming, increases
animal usage, and is only semi-quantitative. Alternatively, virus-specific BMem frequencies can
be determined by limiting dilution analysis after an in vitro stimulation step to initiate the
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proliferation and differentiation of BMem into Ab-secreting plasma cells (Nanan, Heinrich et al.
2001). Slifka and Ahmed (Slifka and Ahmed 1996) optimized this approach by applying the
ELISPOT assay for the rapid and sensitive detection of plasma cell formation, and used the assay
to determine the frequencies of BMem generated by lymphocytic choriomeningitis virus infection.
To use this assay as a reliable and broad method for measuring BMem frequencies, this method has
to be tested on other virus system.

CONCLUSION
The purpose of vaccination is to provide protection from disease via induction and recall
of immunological memory responses. Despite the important contribution that a BMem response
makes to resistance to infection, there have been few quantitative studies of the BMem pool
induced by virus infection or vaccination. One commonly held premise is that a live virus
infection of the respiratory tract is likely to induce the “optimal” BMem pool in terms of providing
resistance to re-infection. However, no studies have been conducted to provide a quantitative
basis for this premise. Comparative studies of the nature of the MBC pool induced by live virus
infection and by different approaches to vaccination are clearly required. Fundamental questions
to be addressed include: “How many virus-specific BMem are there?”, “What is their anatomical
distribution?”, and “What Ab isotypes do they express?” The answers to such questions are
essential if rational decisions are to be made about the development and optimization of
vaccination regimens.
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The work described in this dissertation has been aimed at (i) developing a sensitive and
reproducible limiting dilution assay (LDA) for measuring influenza-specific BMem frequencies
and (ii) applying the influenza-specific BMem assay to determine the state of influenza-specific B
cell memory generated by respiratory tract infection, and also by different forms of vaccination
with inactivated virus in a mouse model. We found ASCs and BMem preferentially localize in the
lung after i.n. infection whereas, there is minimal localization of the components of B cell
memory in the lung after i.m. vaccination. Thus, we concluded that the lung is a repository of B
cell memory after influenza infection and must be taken into account in the development of
effective local vaccines to protect specifically respiratory tract. However, there are many
remaining questions concerning the functional significance and anatomical location of B cell
memory in the lung. It is also need to be determined how homing mechanisms and local
retention of B cell memory is regulated.
Although these studies have focused on influenza infection and vaccination, it is
anticipated that the findings will be generally applicable to other viruses that target the
respiratory tract.
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APPENDIX
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Figure 1. Cytokine interplay in innate and adaptive immunity. Influenza A virus is capable of
infecting both epithelial cells in respiratory tract and tissue macrophages. Infected epithelial cells
produce RANTES, MCP-1, IL-8 and type I IFN, whereas macrophages produce various
chemokines that attract monocytes/macrophages and proinflamatory cytokines such as IL-1,
TNF-α that are involved in functional maturation of tissue macrophages and dendritic cells.
Cytokines and chemokins produced following influenza infection lead to massive infiltration of
leukocytes from the circulation to the lung which is hallmark of the host defense mechanism
against viral infection. In addition, Matured macrophages and dendritic cells exit the lung
through lymphatic system and reach regional lymph nodes to initiate adaptive immune response.
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Table 1. Links between influenza infection and chemokine/cytokine-mediated
immunopathogenesis (adapted from La Gruta, Kedzierska et al. 2007)

Chemokine/cytokine

IFN-γ

TNF-α

IL-1

Function

Produced by

Inhibits viral replication
Stimulates CTL mediated killing
Increases MHC I expression
Activates macrophages and neutrophils
Promotes T-cell proliferation

T cells, NK cells

Direct antiviral effects
Neutrophil chemoattractant
Stimulates macrophage phagocytosis and production
of IL-1
Increases vascular permeability

T cells
Monocytes/macrophages
Dendritic cells
Neutrophils

Increases expression of adhesion factors on
endothelium
Increases vascular permeability
Stimulates IL-6 production

Monocytes/macrophages
Dendritic cells

Respiratory epithelium
T cells
Monocytes/macrophages
Dendritic cells

IL-6

Pro-inflammatory cytokine
Activates T cells

MIP-1b (CCL4)

Monocyte, T cell chemoattractant
Activates neutrophils

Monocytes/macrophages
Neutrophils
T cells
Dendritic cells

MIG (CXCL9)

Monocyte and T-cell chemoattractant

Respiratory epithelium
Monocytes/macrophages

IP-10 (CXCL10)

Monocyte and T-cell chemoatrractant

Monocytes/macrophages
T cells
Respiratory epithelium

RANTES (CCL5)

Monocyte, T cell, DC chemoattractant
Activates T cells

T cells
Respiratory epithelium

IL-8 (CXCL8)

Neutrophil and T-cell chemoatrractant
Activates neutrophils

Respiratory epithelium
Monocytes/macrophages
Neutrophils
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Table 2. Mouse immunoglobulin isotypes
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Chapter 2
A strategy for selective, CD4+ T cell-independent
activation of virus-specific memory B cells for
limiting dilution analysis
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Research described in this chapter is a modified version of an aticle published in 2006 in Journal
of immunological methods by Xiaofeng Li, Daisy J. Vanitha, Hye Mee Joo, Yuxia He, Barry T.
Rouse and Mark Y. Sangster.

Li X, Vanitha DJ, Joo HM, He Y, Rouse BT, Sangster MY. A strategy for selective, CD4+ T
cell-independent activation of virus-specific memory B cells for limiting dilution analysis. J
Immunol Methods. 2006 Jun 30;313(1-2):110-8. Copyright © 2006 by Elsevier B.V.
In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper includes (1)
planning experiments and data analysis (2) interpretation of the results (3) Compiling and
interpretation of the literature (4) understanding how results fit with the literature (5) Preparation of
graphs, figures and tables (6) editing.

Abstract
Complete characterization of the B cell response to infection or vaccination is dependent
on accurate quantitation of the memory B cell (BMem) pool. An established method for measuring
BMem frequencies is limiting dilution analysis based on in vitro stimulation of BMem to divide and
differentiate into antibody-secreting cells (ASCs). The presence of specific antibody then serves
to identify cultures positive for precursor BMem. The sensitivity of this approach is critically
dependent on optimal in vitro BMem activation. To develop a limiting dilution assay (LDA) for
measuring influenza-specific BMem frequencies, we evaluated strategies for the in vitro
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stimulation of influenza-specific MBCs. An ELISPOT assay to enumerate influenza-specific IgG
BMem was used as the readout for BMem activation. Culture of influenza-specific BMem with
influenza-infected splenocytes was effective for BMem activation, but T cell-associated factors
were required for optimal LDA sensitivity and clonal expansion of activated BMem. However,
optimal influenza-specific BMem activation was T cell-independent when BMem were simply
cultured with -propiolactone (BPL)-inactivated influenza virus particles (BPL-flu). BPL-flu did
not stimulate naïve B cells to produce influenza-specific IgG, demonstrating that only BMem were
activated. In addition, BPL-flu acted selectively and only activated influenza-specific BMem, not
BMem of other specificities. Analysis of influenza-specific BMem frequencies in different
anatomical locations in influenza-immune mice established that in vitro stimulation with BPL-flu
provided the basis for a sensitive and reproducible LDA. Extending our studies to the herpes
simplex virus (HSV) system, we demonstrated that HSV-specific BMem cultured with BPLinactivated HSV were selectively activated to IgG secretion in the absence of T cells. Our studies
identify BPL-inactivated viral particles as a valuable tool for selective, T cell-independent
activation of virus-specific BMem in vitro. This strategy eliminates the influence of poorly-defined
T cell-associated factors on BMem frequency determinations.

Introduction
The B cell response to infection or vaccination generates antibody-secreting plasma cells
and a population of antigen-specific memory B cells (BMem). Typically, BMem are long-lived
products of the germinal center reaction that express high affinity, isotype-switched
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immunoglobulin receptors and distribute to lymphoid tissues throughout the body (McHeyzerWilliams and McHeyzer-Williams 2005). Unlike plasma cells, BMem are quiescent, nonantibody-secreting cells. It is only upon activation that BMem divide and differentiate into
antibody-secreting cells (ASCs), a process that generally occurs in vivo when BMem encounter
recall antigen. The activation requirements of BMem are less stringent than those of naïve B cells
(Yefenof, Sanders et al. 1986), but still remain incompletely understood. In at least some
experimental systems, BMem activation is dependent on CD4+ T cell help (Ochsenbein,
Pinschewer et al. 2000).
Quantitative studies of antigen-specific BMem have frequently focused on responses to
simple haptens, since these molecules can be tagged with fluorochromes for flow cytometric
identification of BMem expressing specific receptors (Shimoda, Nakamura et al. 2001; Blink,
Light et al. 2005). Recently, biotinylated influenza virus hemagglutinin was used to enumerate
hemagglutinin-specific B cells by flow cytometry (Doucett, Gerhard et al. 2005). The analysis of
antigen-specific B cells by flow cytometry has obvious appeal, but currently this approach
provides an incomplete picture of the BMem pool generated by many pathogens. The B cell
response to pathogens is generally complex, being directed against multiple, often poorlydefined epitopes on multiple molecules.
An alternative approach to BMem quantitation that may better accommodate the diverse B
cell response to pathogens is the limiting dilution assay (LDA). This assay is based on the in
vitro stimulation of BMem to divide and differentiate into ASCs, with the presence of specific
antibody serving to identify cultures positive for precursor BMem. The period required for BMem
stimulation can be minimized by applying an ELISPOT assay to directly detect antibody23

secreting daughter cells (Slifka and Ahmed 1996). A key requirement for accurate MBC
quantitation by LDA is effective in vitro BMem activation. One approach is to non-specifically
activate B cells with polyclonal stimulators (Nanan, Heinrich et al. 2001; Crotty, Aubert et al.
2004), but massive cell proliferation and antibody production are likely to have detrimental
effects on culture conditions and assays for specific antibody. Alternatively, a more selective
activation of BMem may be achieved by incubation with appropriate antigenic forms (Hebeis,
Klenovsek et al. 2004) . Virus-specific MBCs have been activated by culture with virus-infected
cells or purified viral particles (Jones and Ada 1987; Slifka and Ahmed 1996; Moser and Offit
2001), but the in vitro culture conditions required for optimal BMem activation and clonal
expansion are not well defined.
The BMem response to a previously encountered virus contributes substantially to immune
protection, and is likely to be a key determinant of the effectiveness of inactivated viral vaccines
that target the humoral arm of the immune system. It is therefore surprising that little quantitative
information on the BMem pool induced by viral infection or vaccination has been collected.
Notably, Slifka and Ahmed used a limiting dilution approach to determine lymphocytic
choriomeningitis virus (LCMV)-specific BMem frequencies. In vitro BMem activation was
achieved by incubation with splenocytes from LCMV carrier mice, a cell population heavily
infected with the virus. Supplementation of stimulation cultures with ConA-conditioned medium
increased LCMV-specific MBC frequencies, indicating a requirement for T cell-derived factors
(Slifka and Ahmed 1996).
The current report describes the development of a limiting dilution assay for determining
influenza virus-specific BMem frequencies in a mouse model. Our initial strategy of using
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influenza virus-infected splenocytes to activate specific BMem required T cell-associated factors
for optimal effectiveness. However, the use of -propiolactone (BPL)-inactivated influenza virus
particles achieved T cell-independent BMem activation. Extension of our studies to a mouse
model of herpes simplex virus (HSV) infection demonstrated that BPL-inactivated HSV particles
activated HSV-specific BMem in the absence of T cells. Our findings identify a simple, broadly
applicable strategy for in vitro activation of virus-specific BMem for limiting dilution analysis.
Using this strategy, the proportion of CD4+ T cells present in culture is unlikely to be a factor in
BMem activation, and any detrimental effects of viral replication on leukocyte function are
eliminated.

Materials and Methods
Mice
C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice
were housed under specific pathogen-free conditions until infection, and thereafter in BSL2
containment. Female mice were used in all studies and were infected at 8-10 wk of age. The
Animal Care and Use Committee of the University of Tennessee approved all animal procedures.
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Viruses
Influenza virus A/HKx31 (H3N2) grown and titrated in the allantoic cavity of
embryonated hen’s eggs was obtained from Dr. P. C. Doherty (St. Jude Children’s Research
Hospital, Memphis, TN). The KOS strain of HSV-1 was grown and plaqued in Vero cells. HSV
was concentrated from clarified tissue culture grown virus by centrifugation at 75,000g for 1h.
For HSV inactivation by BPL treatment, concentrated virus in 0.1% BPL (Acros Organics), 0.1
M Tris-HCl (pH 7.5) was incubated for 2 h at 37°C with frequent mixing, and then held
overnight at 4°C. Complete inactivation was confirmed by the absence of cytopathic effect in
Vero cell monolayers inoculated with the treated virus. Preparations of sucrose gradient-purified
and BPL-inactivated influenza A/HKx31 were purchased from Charles River (Wilmington, MA).
Viral protein concentrations were determined using the Bio-Rad protein assay (Bio-Rad,
Hercules, CA). All virus preparations were stored at -80°C.

Infection and sampling
Mice were anesthetized with Avertin (2,2,2-tribromoethanol) given intraperitoneally, and
then infected intranasally with 106.8 50% egg infectious doses of influenza virus (30 l in PBS).
Influenza-immune mice were sampled 60-90 days after infection. Mice were infected
intraperitoneally with 106 PFU of HSV, and sampled 30-45 days after infection. The right
posterior mediastinal lymph node (MLN), inguinal lymph nodes (ILN), and spleen were
collected and gently disrupted to generate single cell suspensions. Splenocytes were cleared of
erythrocytes by ammonium chloride lysis. Nasal-associated lymphoid tissue (NALT) was
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collected attached to the palate (Asanuma, Thompson et al. 1997) and cells were released by
teasing.

Memory B cell assay
Single-cell suspensions of immune cells were prepared in IMDM (Invitrogen, Carlsbad,
CA) containing L-glutamine (2 mM), sodium pyruvate (1 mM), penicillin (100 IU/ml),
streptomycin (100 g/ml), gentamicin (10 g/ml), and 5 x 10-5 M -mercaptoethanol (designated
B cell medium, BCM), and supplemented with 10% fetal bovine serum (FBS). Initially, immune
cells were stimulated in vitro by culture with virus-infected splenocytes. Two-fold dilutions of
immune cells (12 wells per dilution) were incubated in 96-well flat-bottom tissue culture plates
(Corning) containing 5 x 105 irradiated (3,000 rad) syngeneic naïve spleen cell feeders and 5 x
105 irradiated (3,000 rad) syngeneic virus-infected splenocytes. The total volume per well was
200 l. Plates were incubated for 4 days (routinely) at 37°C in a humidified atmosphere
containing 5% CO2. After incubation, cells in each well were washed 3 times as described
previously (Slifka and Ahmed 1996). Briefly, this involved removing a volume of supernatant,
adding fresh BCM containing 2% FBS, and pelleting the cells by centrifugation. After the final
wash, cells in each well were resuspended in the remaining volume of medium and transferred to
antigen-coated plates for enumeration of virus-specific ASCs by ELISPOT assay (described
below). Pre-existing virus-specific ASC numbers in immune cell populations at the time of
sampling were determined by direct ex vivo ELISPOT assay. After in vitro BMem activation and
ELISPOT analysis, individual wells were scored positive for virus-specific BMem if progeny ASC
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numbers were greater than the mean pre-existing ASC number plus 3 standard deviations. A
minimum of 6 progeny ASCs were also required for a well to be scored positive. In an
alternative strategy, graded doses of immune cells were stimulated in vitro by culture with 106
irradiated (3,000 rad) syngeneic naïve spleen cell feeders plus BPL-inactivated viral particles
(generally. 0.05-0.1 g/well). On occasion, mitomycin C treatment (Slifka and Ahmed 1996)
was used instead of irradiation to block proliferation of naïve spleen cell feeders. Otherwise, the
BMem assay was performed as described above. The virus-specific BMem frequency was calculated
from the number of negative wells per cell dilution by extrapolation to the dilution that gave 37%
negative wells (Topham and Doherty 1998). In some experiments, in vitro stimulation cultures
were supplemented with 105 CD4+ T cells enriched from the spleens of immune mice by
negative selection to >85% purity (Topham and Doherty 1998). Briefly, immune splenocytes
treated with anti-MHC class II (TIB-120) and anti-CD8 (53-6.72) were incubated with sheep
anti-mouse and sheep anti-rat Ig-coupled Dynabeads (Invitrogen), and a magnet was applied
according to the manufacturer’s instructions to remove labeled cells. Input cell volumes in the
BMem assay were adjusted to maintain the total volume per well at 200 l. T cell-depleted
immune splenocytes (<1% CD3+ T cells) were prepared by complement lysis of cells coated with
anti-Thy-1.2 mAb (AT83). Splenocytes were depleted of CD19+ B cells (<0.6%) by treatment
with biotinylated anti-CD19 mAb (1D3; BD Biosciences, San Diego, CA), 1 g/106 cells,
followed by incubation with streptavidin-coupled Dynabeads (Invitrogen), and magnetic removal
of labeled cells according to the manufacturer’s instructions. Cell populations were characterized
by flow cytometry using FITC-conjugated mAbs to CD3 (145-2C11) and CD4 (RM4-5); PE-
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conjugated mAbs to CD8 (53-6.7) and CD19 (1D3); and APC-conjugated anti-CD3 mAb
(145-2C11; BD Biosciences) as staining reagents.

Influenza-infected splenocytes
Up to 108 erythrocyte-free naïve splenocytes in HBSS were pelleted and resuspended in 1
ml HBSS. Influenza virus stock was added to give the required multiplicity of infection, and the
preparation was incubated for a total of 4 h with occasional mixing in a 37°C waterbath. After 1
h of the incubation period, 10 ml BCM containing 10% FBS was added per ml of cell suspension.
The infected cells were then irradiated (3,000 rad), washed once, and resuspended in complete
BCM.

ELISPOT assay
The ELISPOT assay was adapted to enumerate influenza-specific or HSV-specific IgG
ASCs. A preparation of concentrated viral particles was disrupted for 10 min at room
temperature in a 1 in 10 dilution of disruption buffer (0.5% Triton X-100, 0.6 M KCl, and 0.05
M Tris-HCl, pH 7.5) in PBS, further diluted in PBS, and plated at 1 g/well in nitrocellulosebottomed 96-well Multiscreen HA filtration plates (Millipore, Bedford, MA). After overnight
incubation at 4°C, plates were washed with PBS, and blocked with BCM containing 10% FBS.
Plates were emptied by flicking, and cell suspensions (including resuspended cells from 96-well
MBC assay plates) were added in volumes of approximately 100 l/well. After incubation for 329

4 h at 37°C in a humidified atmosphere containing 5% CO2, plates were thoroughly washed with
PBS alone and PBS containing 0.1% Tween 20. Alkaline phosphatase-conjugated goat antimouse IgG (Southern Biotechnology, Birmingham, AL) diluted to 2 g/ml in PBS containing 5%
bovine serum albumin was added (100 l/well), and the plates were incubated overnight at 4°C.
The plates were then washed extensively with PBS alone and PBS containing 0.1% Tween 20,
including washing the underside of the nitrocellulose filters. Spots were developed at room
temperature by the addition of 1 mg/ml of 5-bromo-4-chloro-3-indolyl phosphate (Sigma, St.
Louis, MO) in diethanolamine buffer (10% diethanolamine, 0.1 M NaCl, 5 mM MgCl2, and 0.1
M Tris-HCl, pH 9.5), 100 l/well. After optimal spot development, plates were washed with PBS
and dried, and spots representing individual ASCs were counted using an Olympus SZX9
stereozoom microscope.

Statistics
Statistical comparisons of mean values were performed using the nonparametric MannWhitney U test for unpaired samples.
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Results
In vitro activation of influenza virus-specific BMem using virus-infected splenocytes
Our primary goal of determining influenza-specific BMem frequencies by limiting dilution
assay required an effective method for the in vitro activation of influenza-specific BMem. Initial
experiments evaluated the use of irradiated, influenza-infected syngeneic splenocytes as
“stimulators” for this purpose, since a similar approach activates BMem in the LCMV system
(Slifka and Ahmed 1996). In addition, virus-infected splenocytes stimulate the activation of
primed, influenza-specific CD4+ T cells, and these would be expected to contribute cytokines to
the cultures (Sarawar and Doherty 1994). Limiting, two-fold dilutions of spleen cells from
influenza immune mice (the source of BMem) were cultured in 96-well plates with virus-infected
stimulator cells. The starting input dose of immune spleen cells was 105. After 4 days incubation,
cells were resuspended and transferred to influenza-coated, 96-well ELISPOT plates for the
enumeration of influenza-specific ASCs. For each input dose of immune cells, post-stimulation
ASC numbers were compared to the number of pre-existing influenza-specific ASCs in the
immune spleen, determined by ELISPOT assay at the time of sampling. Wells were scored as
positive for influenza-specific BMem if the post-stimulation ASC count was greater than the mean
background count plus 3 SD. All post-stimulation ASC counts of ≤5 were considered negative.
The influenza-specific BMem frequency was calculated from the number of negative wells per cell
dilution by extrapolation to the dilution that gave 37% negative wells (Topham and Doherty
1998). Studies of the LCMV system by Slifka and Ahmed validated the ELISPOT-based limiting
dilution assay for quantitation of virus-specific BMem (Slifka and Ahmed 1996).
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Influenza virus is completely cleared from sublethally infected mice by 10-12 days after
infection, corresponding to a decrease in the number of influenza-specific ASCs in responding
lymphoid tissue (Liang, Hyland et al. 2001). By 8 weeks or more after infection, the mean
number of influenza-specific IgG ASCs in the spleen at an input dose of 105 immune cells was
<10. In contrast, stimulation of the same input dose of cells with virus-infected splenocytes
typically generated uncountable (>100) influenza-specific IgG ASCs. No influenza-specific IgG
ASCs were detected after in vitro stimulation of splenocytes from naïve mice, demonstrating that
the ASCs generated by stimulation of immune splenocytes reflected activation of virus-specific
BMem.
Influenza-specific BMem frequencies were determined after in vitro stimulation with virusinfected splenocytes prepared using a range of multiplicities of infection (MOIs). Highest
frequencies were obtained at MOIs ranging from 0.01–1.0 (Table I), and an MOI of 0.1 was
selected for subsequent experiments using virus-infected splenocytes.
An important question concerned the requirement for CD4+ T cell help for optimal in
vitro BMem activation. To evaluate the contribution of T cells, we determined influenza-specific
BMem frequencies using total or T cell-depleted immune splenocytes. Results were standardized
by expressing the BMem frequency for CD19+ cells. Depletion of CD19+ cells to <0.6%
eliminated influenza-specific BMem from immune splenocytes (data not shown), indicating that
BMem reside in the CD19+ population (Bell and Gray 2003; Blink, Light et al. 2005). The use of
total immune splenocytes gave up to three-fold higher frequencies than did the T cell-depleted
populations (Table II), indicating an important role for T cell-associated factors during in vitro
stimulation. Although the key T cell-associated factors in this system have not been defined, it is
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likely that they are derived primarily from CD4+ T cells (Sarawar and Doherty 1994). To
determine whether CD4+ T cell help was limiting even during stimulation of total immune
splenocytes, a cell population that contained approximately 20% CD4+ T cells, we evaluated the
effect of supplementing the stimulation cultures with enriched CD4+ T cells from influenzaimmune mice. Addition of enriched, immune CD4+ T cells (105 cells/well; >85% CD4+ T cells)
to total immune splenocytes cultured with virus-infected stimulator splenocytes had little effect
on the number of wells scored positive for BMem (and hence the BMem frequency), but increased
the number of ASCs generated in positive wells (data not shown). Taken together, our findings
indicate that CD4+ T cell-derived factors promote the activation and clonal expansion of
influenza-specific BMem during in vitro culture with virus-infected splenocytes.

In vitro activation of influenza virus-specific BMem using BPL-inactivated virus particles
Recently, Hebeis and colleagues demonstrated that the form of challenge antigen
determines the CD4+ T cell dependence of BMem responses. The in vivo BMem response elicited
by antigen in the form of non-replicating, virus-like particles was CD4+ T cell-independent,
whereas that elicited by soluble monomeric antigen was not (Hebeis, Klenovsek et al. 2004).
Apparently, the repetitive arrangement of antigens on the virus-like particles provided a potent
activating signal for BMem that circumvented the requirement for CD4+ T cell help. We therefore
tested whether BPL-inactivated influenza virus particles (BPL-flu) would effectively activate
virus-specific BMem in vitro for limiting dilution analysis. Graded doses of immune splenocytes
were simply cultured with a feeder population of irradiated naïve syngeneic splenocytes to which
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BPL-flu had been added. Titration of the input amount of BPL-flu established that effective
influenza-specific BMem activation was achieved with as little as 0.01 g/well (Fig. 1A). BPL-flu
was used at 0.1 g/well in subsequent experiments. BMem frequencies were similar after in vitro
stimulation of immune cells with BPL-flu for periods of 3, 4, or 5 days (data not shown), and an
incubation period of 4 days was used routinely. No influenza-specific IgG ASCs were generated
during the incubation of splenocytes from naïve mice with BPL-flu, demonstrating that only
BMem are activated. BMem frequencies were comparable when total immune splenocytes were
stimulated in vitro with BPL-flu or with virus-infected splenocytes (Table III). However, a
consistent trend was for higher ASC counts in positive wells after BPL-flu stimulation,
indicating that this approach generated greater clonal expansion of BMem.
We next evaluated the requirement for CD4+ T cells during in vitro BMem activation with
BPL-flu. T cell-depleted splenocytes were stimulated with BPL-flu, or with virus-infected
splenocytes supplemented with enriched, immune CD4+ T cells to provide optimal BMem
activation. In two separate experiments, stimulation with BPL-flu produced BMem frequencies
similar to those obtained using virus-infected stimulators plus immune CD4+ T cells, and
approximately 2.4-fold greater than those obtained by stimulation with virus-infected
splenocytes alone (Table IV). In addition, stimulation with BPL-flu or with virus-infected
splenocytes plus immune CD4+ T cells resulted in similar clonal expansion of BMem, as indicated
by the number of ASCs generated in positive wells (Fig. 2). These experiments emphasize the
contribution of CD4+ T cell-associated factors to in vitro BMem activation. Importantly, our
findings indicate that BPL-flu effectively activates influenza-specific BMem in vitro in the
absence of CD4+ T cells.
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To assess the specificity of BPL-flu in the activation of BMem, we cultured splenocytes
from HSV-immune mice with BPL-flu. No HSV-specific ASCs were generated in these cultures,
demonstrating that BPL-flu activates only influenza-specific BMem (Fig. 1B). LPS was below the
level of detection at the BPL-flu concentrations used for activating influenza-specific BMem.

Measurement of influenza-specific BMem frequencies in different anatomical locations
We next determined whether in vitro stimulation with BPL-flu provided the basis for a
sensitive limiting dilution assay to measure influenza-specific BMem frequencies in different
anatomical locations. Cell populations for analysis were prepared from the NALT, MLN, spleen,
and ILN of mice 8-12 weeks after i.n. influenza infection. The tissues sampled included sites
(NALT, MLN) that generate strong B cell responses to influenza infection of the respiratory tract
(Liang, Hyland et al. 2001; Sangster, Riberdy et al. 2003), and a site (ILN) that does not. Our
analysis demonstrated influenza-specific BMem in all sites examined (Fig. 3), supporting the
notion that BMem distribute to lymphoid tissues throughout the body (Bachmann, Kundig et al.
1994). However, this distribution was not equal. Significantly higher BMem frequencies were
present in the NALT and MLN compared with the spleen and ILN, indicating a concentration of
BMem in lymphoid tissue associated with the site of infection even long after the infectious agent
has been cleared. This preliminary analysis establishes that our approach is sufficiently sensitive
and reproducible to demonstrate differences between anatomical locations in influenza-specific
BMem frequencies.
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BPL-inactivated HSV activates HSV-specific BMem for limiting dilution analysis
Our studies of the influenza system raised the possibility that the use of BPL-inactivated
virus particles may have broad applicability for in vitro BMem activation. We therefore turned to a
mouse model of HSV infection and analyzed approaches to the in vitro activation of HSVspecific BMem for limiting dilution analysis. An ELISPOT assay for HSV-specific IgG ASCs was
used to detect BMem activation and plasma cell formation. Splenocytes from HSV-immune mice
(the source of BMem) were cultured in limiting dilution format with feeder splenocytes to which
BPL-inactivated HSV (BPL-HSV) had been added. This strategy effectively activated HSVspecific BMem at BPL-HSV doses as low as 0.0025 g/well (Fig. 1B). No HSV-specific IgG
ASCs were generated from naïve splenocytes stimulated with BPL-HSV, demonstrating that
only BMem were activated. The specificity of BPL-HSV stimulation was tested by incubating
splenocytes from influenza-immune mice with BPL-HSV. No influenza-specific ASCs were
generated in these cultures, demonstrating that BMem activation by BPL-HSV is antigen specific
(Fig. 1A). LPS was undetectable in the BPL-HSV preparation.
To evaluate the requirement for T cells during in vitro BMem activation by BPL-HSV,
intact or T cell-depleted immune splenocytes were incubated in limiting dilution format with
irradiated feeder splenocytes plus BPL-HSV. HSV-specific MBC frequencies (adjusted to
accommodate differences in the proportion of CD19+ input cells) were similar for the intact and
T cell-depleted immune populations (Table V). Our findings indicate that BPL-HSV (like BPLflu in the influenza system) effectively activates virus-specific BMem in vitro in the absence of T
cell-associated factors.
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Discussion
The measurement of virus-specific BMem frequencies by limiting dilution analysis
typically relies on BMem activation and differentiation during a period of in vitro stimulation.
Cultures are then scored as positive or negative for virus-specific BMem on the basis of specific
antibody secretion. In this report, we describe a strategy utilizing BPL-inactivated virus particles
for the in vitro activation of virus-specific BMem. This strategy selectively activates virus-specific
BMem and, importantly, achieves this without a requirement for CD4+ T cell-associated factors.
It is well-established that BMem have less stringent activation requirements than do naïve
B cells. In fact, this is reflected in the limiting dilution assay described in this report, since only
B cells from immune mice, but not from naïve mice, were stimulated in vitro to produce virusspecific antibodies. However, the requirements for optimal BMem activation in vitro are not
known. Initially, we used virus-infected splenocytes as “stimulators” for the activation of
influenza-specific BMem. This approach produced consistently higher influenza-specific BMem
frequencies when total, compared with T cell-depleted, immune splenocytes were tested.
Supplementation of total immune splenocytes with enriched immune CD4+ T cells had no effect
on the influenza-specific BMem frequency, but did increase the number of ASCs generated in
positive wells. Thus, when influenza-infected splenocytes were used as stimulators, there was a
minimum requirement for T cell-associated factors to promote BMem activation and plasma cell
formation. Exceeding this minimum requirement by adding immune CD4+ T cells simply
increased the number of plasma cells formed, presumably by driving the clonal expansion of
activated BMem. Although the precise nature of the T cell “help” remains to be determined, T
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cell-derived cytokines are likely to be important factors. In studies of the LCMV system, BMem
activation during culture with virus-infected splenocytes was improved by supplementary
cytokines (Slifka and Ahmed 1996).
Our studies demonstrate that in vitro BMem activation with BPL-inactivated virus particles,
at least in the influenza and HSV systems, circumvents the requirement for T cell-associated
factors. This strategy provides the basis for a limiting dilution assay that can be applied with
confidence to determine BMem frequencies in lymphoid populations that differ substantially in the
proportion of CD4+ T cells. For instance, in our analysis of influenza-specific BMem frequencies
in different anatomical locations, the percentage (mean±SD) of CD4+ T cells in the tissues
sampled were 5.6±0.3 (NALT), 20.1±1.6 (spleen), 23.6±0.9 (MLN), and 31.7±2.6 (ILN). The
use of BPL-flu for in vitro BMem activation minimized the possibility that results would be
influenced by the proportion of CD4+ T cells present in the cultures.
Recently, Hebeis and colleagues emphasized the importance of antigen form in the
induction of CD4+ T cell-independent BMem responses in vivo (Hebeis, Klenovsek et al. 2004).
The effectiveness of BPL-inactivated particles in our studies may be due to repetitively arranged
epitopes that cross-link B cell receptors and generate potent activating signals. If this is the case,
then the BMem activated will only be those specific for epitopes displayed by molecules on the
surface of virions. Generally, however, the most reactive B cell determinants are those present on
the abundant viral surface glycoproteins, and it is these determinants that are the targets of
neutralizing antibody responses. The majority of influenza-specific antibodies generated during
infection, including the primary protective antibodies, target the hemagglutinin and
neuraminidase envelope glycoproteins (Marshall, Sealy et al. 1999). It remains to be determined
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whether culture with BPL-flu activates the same or a more restricted set of BMem specificities
than does culture with influenza-infected splenocytes. The effectiveness of BPL-inactivated viral
particles as BMem activators raises the possibility that antigens appropriately arranged on an
artificial lipid vesicle (Huckriede, Bungener et al. 2003) may also be used for in vitro BMem
activation. This strategy may permit the activation of BMem specific for selected molecules.
Numerous strategies for viral inactivation may generate particles that are suitable for in
vitro BMem activation. An important consideration is the need to achieve viral inactivation with
minimal modification of B cell epitopes. In the current study, viral inactivation was achieved by
treatment with BPL, a potent alkylating agent that acts primarily through modification of the
viral genome (Perrin and Morgeaux 1995). Compared with other methods of viral inactivation,
BPL treatment completely inhibits replicative capacity with much less severe effects on protein
structure (Sangster, Mo et al. 1997).
In summary, this report describes a simple, inexpensive strategy for selective, virusspecific BMem activation in vitro. Most importantly, BMem activation and clonal expansion is
achieved independently of poorly-defined CD4+ T cell-associated factors, thus eliminating a
variable that adds uncertainty to estimates of BMem frequencies. In addition, the use of inactivated
virus particles for BMem activation avoids problems that may be caused by live virus. Although
this may not be a significant concern with influenza virus, many viruses including HSV induce
the functional impairment or death of leukocytes infected in vitro (Brucher, Domke et al. 1984;
Jones, Fernandez et al. 2003). The fact that only antigen-specific BMem are activated avoids the
extensive cell proliferation and detrimental effects on cell culture conditions associated with the
use of polyclonal B cell activators. This makes the strategy particularly suitable for limiting
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dilution assays performed in 96-well plates and requiring incubation for three or more days.
Finally, our demonstration that the strategy is effective with both influenza virus and HSV
suggests that it is likely to have broad applicability in a wide range of viral systems.
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APPENDIX
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Table I
Influenza-specific BMem frequencies determined after in vitro stimulation
with virus-infected splenocytes prepared using different multiplicities of
infectiona
MOI

BMem Frequencyb

5

1.4 x 104

1

8.8 x 103

0.1

8.2 x 103

0.01

7.7 x 103

0.001

2.3 x 104

a

Total splenocytes from influenza-immune mice were incubated in limiting
dilution format with influenza-infected syngeneic splenocytes.

b

Numbers represent the reciprocal of calculated influenza-specific BMem
frequencies per total splenocytes. Results are representative of two
separate experiments.
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Table II
Comparison of influenza-specific BMem frequencies determined using total or
T cell-depleted immune splenocytesa
BMem Frequencyb
Immune splenocytes
Spleen 1

Spleen 2

Spleen 3

Total

1.3 x 104

1.6 x 104

5.8 x 103

T cell-depleted

4.0 x 104

2.8 x 104

8.3 x 103

a

Total or T cell-depleted splenocytes from influenza-immune mice were incubated
in limiting dilution format with influenza-infected syngeneic splenocytes.

b

Numbers represent the reciprocal of calculated influenza-specific BMem frequencies
per CD19+ splenocytes.
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Table III
Influenza-specific BMem frequencies determined after in vitro stimulation with
virus-infected splenocytes or BPL-flu
In vitro stimulationa

BMem Frequencyb
Experiment 1

Experiment 2

Experiment 3

Virus-infected splenocytes

7.1 x 103

7.3 x 103

8.2 x 103

BPL-flu

8.3 x 103

7.1 x 103

5.6 x 103

a

Total splenocytes from influenza-immune mice were cultured in limiting dilution
format, together with either influenza-infected syngeneic splenocytes or BPL-flu.

b

Numbers represent the reciprocal of calculated influenza-specific BMem frequencies
per total splenocytes.
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Table IV
In vitro stimulation with BPL-flu activates influenza-specific BMem in the absence of
CD4+ T cells
In vitro stimulationa

CD4+ T cellsb

BMem Frequencyc
Experiment 1

Experiment 2

Virus-infected splenocytes

-

8.3 x 103

1.1 x 104

Virus-infected splenocytes

+

4.3 x 103

4.5 x 103

BPL-flu

-

3.4 x 103

4.1 x 103

a

T cell-depleted splenocytes from influenza-immune mice were cultured in limiting
dilution format, together with either influenza-infected syngeneic splenocytes or
BPL-flu.

b

Cultures were supplemented as indicated with enriched CD4+ T cells from the spleens
of influenza-immune mice (105 cells/well; >85% CD4+ T cells; <0.1% CD8+ T cells).
Control cultures established that this population was free of influenza-specific BMem.

c

Numbers represent the reciprocal of calculated influenza-specific MBC frequencies
per CD19+ splenocytes.
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Table V
Comparison of HSV-specific BMem frequencies determined using total
or T cell-depleted immune splenocytesa
BMem Frequencyb
Immune splenocytes
Spleen 1

Spleen 2

Total

4.1 x 103

8.7 x 103

T cell-depleted

4.0 x 103

1.0 x 104

a

Total or T cell-depleted splenocytes from HSV-immune mice were
incubated in limiting dilution format with BPL-HSV (0.01 g/well).

b

Numbers represent the reciprocal of calculated HSV-specific BMem
frequencies per CD19+ splenocytes.
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Reciprocal MBC frequency

A

>100000

80000

60000

40000

20000

0
0.1

0.01

0.001

0.0001

micrograms/well

Reciprocal MBC frequency

B

>100000

80000

60000

40000

20000

0
0.1

0.01

0.001

micrograms/well
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0.0001

Figure 1. Titration of BPL-inactivated viral particles for in vitro BMem activation. (A) Influenzaspecific BMem frequencies determined after in vitro stimulation with different doses of BPL-flu.
Total splenocytes from influenza-immune mice were incubated in limiting dilution format with
irradiated syngeneic splenocytes and different doses of BPL-flu. Parallel sets of control wells
received BPL-HSV instead of BPL-flu. After 4 days incubation, influenza-specific ASC numbers
were determined by ELISPOT assay, and wells were scored as positive or negative for precursor
BMem. Numbers represent the reciprocal of calculated influenza-specific BMem frequencies per
total splenocytes. No influenza-specific ASCs were generated in wells that contained 0.1, 0.01,
or 0.005 g/well of BPL-HSV. Results are representative of two separate experiments. (B)
HSV-specific BMem frequencies determined after in vitro stimulation with different doses of
BPL-HSV. HSV-specific BMem frequencies were determined as described above using total
splenocytes from HSV-immune mice and a range of doses of BPL-HSV. Control wells received
BPL-flu instead of BPL-HSV. An ELISPOT assay for HSV-specific ASCs was used to score
wells as positive or negative for precursor BMem. Numbers represent the reciprocal of calculated
HSV-specific BMem frequencies per total splenocytes. No HSV-specific ASCs were generated in
wells that contained 0.1, 0.01, or 0.005 g/well of BPL-flu. Results are representative of two
separate experiments.
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160

Influenza-specific ASC per well

Flu-infected splenocytes
140

Flu-infected splenocytes
plus CD4 T cells

120

BPL-flu
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*
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Figure 2. Clonal expansion of influenza-specific BMem after in vitro stimulation. Two-fold
dilutions of T cell-depleted splenocytes from influenza-immune mice (12 wells per dilution)
were stimulated in vitro by culture with (i) influenza-infected splenocytes, (ii) influenza-infected
splenocytes plus enriched CD4+ T cells from the spleens of influenza immune mice, or (iii) BPLflu. After 4 days incubation, influenza-specific ASC numbers in each well were determined by
ELISPOT assay. ASC numbers are shown for wells receiving 5 x 104 T cell-depleted splenocytes.
A horizontal bar identifies the mean. Results are representative of two separate experiments. *, P
< 0.0005 compared with cultures stimulated with influenza-infected splenocytes alone.
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Figure 3. Influenza-specific BMem frequencies in different anatomical locations. Cell populations
from influenza-immune mice were cultured for 4 days in limiting dilution format, together with
BPL-flu for in vitro stimulation. An ELISPOT assay for influenza-specific ASCs was used to
identify wells positive for precursor BMem, and BMem frequencies were calculated. Numbers
represent the reciprocal of influenza-specific BMem frequencies per total input cells. A horizontal
bar identifies the mean. *, P < 0.02 compared with NALT and MLN.

50

Chapter 3
Broad dispersion and lung localization of virusspecific memory B cells induced by influenza
pneumonia
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Research described in this chapter is a modified version of an aticle published in 2008 in the
National Academy of Sciences of the USA by Hye Mee Joo, Yuxia He and Mark Y. Sangster.

Joo HM, He Y, Sangster MY. Broad dispersion and lung localization of virus-specific memory B
cells induced by influenza pneumonia. Proc Natl Acad Sci U S A. 2008 March 4; 105(9): 3485–
3490. Copyright © 2008 by The National Academy of Sciences of the USA
In this chapter “our” and “we” refers to me and co-authors. My contribution in the paper includes
(1) the majority of the lab work and (2) most of planning experiments and the data analysis and
(3) Preparation of graphs, figures and tables and (4) editing and discussions.

ABSTRACT
Although memory B cells (BMem) contribute significantly to resistance to infection, BMem
population characteristics that may relate to protective efficacy have received little attention.
Here we report a comprehensive quantitative analysis of virus-specific IgG and IgA BMem
dispersion following transient influenza pneumonia in mice. From early in the response, BMem
circulated continuously and dispersed widely to secondary lymphoid tissues. However, a
complicated picture emerged with BMem frequency differences between secondary lymphoid
tissues indicating an influence of local tissue factors on trafficking. BMem numbers increased and
stabilized at tissue-specific frequencies without contraction of the BMem pool during the period of
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analysis. The lung was notable as a non-secondary lymphoid tissue where a rapid influx of IgG
and IgA BMem established relatively high frequencies that were maintained long-term. Our
findings provide insights into the pattern of BMem dispersion, and emphasize the lung as a
complex repository of immune memory following local infection.

INTRODUCTION
Memory B and T cell subsets generated during adaptive immune responses play a key
role in long-term resistance to infectious agents expressing previously encountered antigens.
After formation in organized secondary lymphoid tissues, the cellular elements of immunological
memory migrate via function-related trafficking pathways and populate lymphoid and nonlymphoid tissues throughout the body. This process establishes a dispersed state of cellular
memory that optimizes protective efficacy. The dispersed CD4 and CD8 memory T cell
populations have been well-characterized (Marshall, Turner et al. 2001; Masopust, Vezys et al.
2001; Reinhardt, Khoruts et al. 2001), but similar comprehensive studies of B cell memory have
not been performed (Anderson, Tomayko et al. 2006).
The two cellular components of B cell memory, long-lived plasma cells (LLPCs) and
memory B cells (BMem), are the products of germinal center reactions in secondary lymphoid
tissue (McHeyzer-Williams and McHeyzer-Williams 2005). LLPCs are classically recognized as
Ab-secreting cells (ASCs) that localize in the bone marrow (BM) and maintain circulating Ab
levels (Slifka and Ahmed 1996). However, long-lasting populations of IgA-secreting cells (in
53

particular) are also established at mucosal surfaces after mucosal immunization where they
provide local protection (Jones and Ada 1986; Liang, Hyland et al. 2001). In contrast to plasma
cells, BMem are quiescent cells that require stimulation to divide and differentiate into ASCs.
Upon encounter with recall antigen, BMem mediate the rapid, vigorous, and high affinity
secondary Ab response that plays a key role in immune protection. The impression from studies
to date is that BMem spread widely to organized lymphoid tissues (Bachmann, Kundig et al. 1994;
Slifka, Antia et al. 1998; Vanitha, Joo et al. 2007), but the full extent of BMem dispersion has not
been determined. It is also unclear whether BMem trafficking patterns relate to the Ab isotype
expressed.
The present study provides a comprehensive quantitative analysis of the dispersed
cellular components of B cell memory induced by influenza A virus infection. Intranasal (i.n.)
influenza virus administration results in a highly localized pulmonary infection because of the
dependence of viral replication on a trypsin-like enzyme that is largely restricted to respiratory
epithelial cells (Steinhauer 1999). Although infected pulmonary dendritic cells are thought to
travel to regional lymphoid tissues and spleen and drive influenza-specific T and B cell
responses, little if any infectious virus is detected outside the lung (Eichelberger, Wang et al.
1991; Hamilton-Easton and Eichelberger 1995; Legge and Braciale 2003). The development of
adaptive immune responses correlates with the clearance of infectious virus from the lung, which
is complete approximately 10 days after infection (Gerhard, Mozdzanowska et al. 1997;
Woodland 2003). The strong influenza-specific B cell response to infection is dominated by the
production of IgG isotypes, but there is also a substantial IgA response. Thus, the model provides
an opportunity to compare the state of both IgG and IgA memory. Our findings provide insights
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into the anatomically dispersed state of B cell memory established during the return to
homeostasis following a transient, localized viral infection of the lung.

Materials and METHODS
Mice and infection
C57BL/6J mice purchased from The Jackson Laboratory (Bar Harbor, ME) were housed
under specific pathogen-free conditions until infection, and thereafter in BSL2 containment.
Female mice were used in all experiments and were infected at 8-10 weeks of age. Influenza
virus A/HKx31 (H3N2) was grown in the allantoic cavity of embryonated hen’s eggs. Mice were
anesthetized with Avertin (2,2,2-tribromoethanol) given intraperitoneally, and then infected i.n.
with 106.8 50% egg infectious doses of influenza virus (30 l in Dulbecco’s PBS). Animal
procedures were approved by the Animal Care and Use Committee of the University of
Tennessee.

Tissue sampling and treatment
Tissues collected from exsanguinated mice were processed to generate single-cell
suspensions in IMDM (Invitrogen, Carlsbad, CA) containing L-glutamine (2 mM), sodium
pyruvate (1 mM), penicillin (100 IU/ml), streptomycin (100 g/ml), gentamicin (10 g/ml), and
5 x 10-5 M -mercaptoethanol (designated B cell medium, BCM), and supplemented with 10%
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FBS. Lymph nodes (CLN, MedLN, ILN, and MesLN) and spleen were disrupted between the
frosted ends of microscope slides. BM cell suspensions were obtained by flushing the femurs and
tibiae. Red blood cells were removed from the spleen and BM preparations by ammonium
chloride lysis. Cell populations from the o-NALT and d-NALT were collected as previously
described (Asanuma, Thompson et al. 1997). Lungs were finely minced and incubated for 1 h at
37°C in BCM containing 10% FBS and 4 mg/ml collagenase type II (Worthington, Lakewood,
NJ). Cells pelleted from the lung digest were resuspended in 40% isotonic Percoll and layered
over 75% isotonic Percoll. After centrifugation at 600g for 20 min at 25°C, cells at the interface
were collected and washed. PP were dissected from the small intestine and washed, and cells
were released by digestion with 2 mg/ml collagenase type I (Worthington) for 30 min at 37°C.
Cells from heparinized blood were collected over Lympholyte-Mammal (Cedarlane, Burlington,
NC) according to the manufacturer’s instructions. Spleens were processed individually;
otherwise tissues were pooled from 2-5 mice to generate sufficient cells for analysis. Cell
populations were characterized by flow cytometry using FITC-conjugated mAb to CD3 (1452C11) and PE-conjugated mAb CD19 (1D3; BD Biosciences) as staining reagents.

Cell enrichment
CD19+ B cells were enriched (purity >95%) from single cell suspensions by MACS using
murine CD19 MicroBeads and LS columns according to the manufacturer’s instructions
(Miltenyi Biotec).
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ELISPOT assay
Influenza-specific ASCs were enumerated by ELISPOT assay as previously described (Li,
Vanitha et al. 2006). Plate-bound secreted Abs were detected using alkaline phosphataseconjugated goat anti-mouse Abs with specificity for IgG or IgA (Southern Biotechnology,
Birmingham, AL).
Memory B cell assay
Influenza-specific BMem frequencies were determined by a previously described LDA
based on in vitro stimulation of BMem to differentiate into ASCs (Li, Vanitha et al. 2006). Briefly,
two-fold dilutions of cells were incubated in 96-well tissue culture plates (routinely 12 wells per
dilution), together with 106 irradiated (3000 rad) syngeneic naïve spleen cell feeders plus propiolactone-inactivated HKx31 (Charles River, Wilmington, MA). After incubation, cells in
each well were transferred to ELISPOT plates for the enumeration of influenza-specific IgG or
IgA ASCs. Pre-existing virus-specific ASC numbers at the time of sampling were determined by
direct ex vivo ELISPOT assay. After in vitro BMem activation and ELISPOT analysis, individual
wells were scored positive for virus-specific BMem if progeny ASC numbers were greater than
twice the mean pre-existing ASC. The approach was modified for tissues that had high numbers
of virus-specific ASCs at the time of sampling. For analysis of BM and d-NALT, wells were
scored positive for BMem relative to unstimulated cultures (without inactivated-HKx31). Lung
cell suspensions prepared 3 wk or more after infection were enriched for CD19+ cells to reduce
ASC numbers before in vitro stimulation, and were compared to unstimulated cultures for
identification of positive wells. The virus-specific BMem frequency was calculated from the
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number of negative wells per cell dilution by extrapolation to the dilution that gave 37% negative
wells (Topham and Doherty 1998). Linearity between the proportion of negative cultures and the
input cell dose indicated direct measurement of BMem. Virus-specific IgG and IgA BMem were
defined as cells that generated IgG and IgA ASCs, respectively, after in vitro stimulation
(Okumura, Julius et al. 1976; Coffman and Cohn 1977). No influenza-specific IgG or IgA ASCs
were detected after in vitro stimulation of spleen, lung, or PP lymphocytes from naïve mice or
from mice infected i.n 8 wk previously with an unrelated virus (murine gammaherpesvirus 68).
IgG and IgA BMem frequencies (per CD19+ cells) in the lung were similar regardless of whether
total or CD19-enriched immune cell populations were analyzed, indicating that results were
independent of tissue-specific non-B cell factors (Mora, Iwata et al. 2006). This was supported
by a BMem analysis of CD19-enriched immune spleen cells stimulated in the presence of CD19depleted immune PP cells, or CD19-enriched immune PP cells stimulated in the presence of
CD19-depleted immune spleen cells (data not shown).

Statistical analysis
Mean values were analyzed using one-way ANOVA and the Tukey post test for multiple
comparisons. The nonparametric Kruskal-Wallis test and Dunn’s post test were used as required
to accommodate values below the limit of assay sensitivity. Tests were performed using
GraphPad software (SanDiego, CA). Values of P < 0.05 were considered statistically significant.
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RESULTS
The primary influenza-specific ASC response to i.n. administered virus has been wellcharacterized. Initially, responses develop in the organized nasal-associated lymphoid tissues (oNALT), which samples antigens in the upper respiratory tract, and in the cervical (CLN) and
mediastinal (MedLN) lymph nodes, which drain the upper and lower respiratory tract,
respectively(Liang, Hyland et al. 2001; Sangster, Riberdy et al. 2003). A delayed response
develops in the spleen, presumably reflecting the transit time of antigen-laden dendritic cells
migrating from the lung. Responses in these sites wane rapidly after the elimination of infectious
virus. The response kinetics are notably different in the BM and in the submucosa of the upper
and lower respiratory tract, where long-maintained populations of influenza-specific ASCs are
established (Jones and Ada 1986; Hyland, Sangster et al. 1994; Liang, Hyland et al. 2001). To
expand our understanding of B cell memory generated by primary influenza pneumonia, we
determined the frequencies of virus-specific ASCs and BMem in a broad range of anatomical
locations 8-12 weeks after infection. At this time, a fully dispersed and stabilized state of B cell
memory would be expected (Slifka, Antia et al. 1998).

Tissue distribution of influenza-specific IgG BMem
Influenza-specific IgG BMem were present in all of the organized lymphoid tissues
examined (Fig. 1A). BMem frequencies expressed as a proportion of total cells were significantly
higher in the o-NALT, MedLN, and Peyer’s patches (PP) than in multiple other sites (Fig. 1A,
legend). Interestingly, IgG BMem preferentially localized in the PP, even though influenza59

specific ASCs were not generated at this site during the primary response to infection (data not
shown). Notably, a relatively high BMem frequency was also present in the lung, a site of plasma
cell concentration (Fig. 1B). The BM contained a substantial plasma cell population, but BMem
were infrequent (<1 in 105) and may have been contaminating cells in the vasculature. BMem were
consistently present in the blood, indicating maintenance of BMem circulation long after viral
clearance.
There was a considerable range in the proportions of CD19+ B cells in the different
anatomical sites examined, with high percentages in the o-NALT and PP and low percentages in
the diffuse(d)-NALT and lung (Fig 1C). Enrichment and depletion experiments established that
the CD19+ population contained all of the influenza-specific BMem detected in our analysis (data
not shown). Therefore, to standardize site-to-site comparisons, influenza-specific IgG BMem
frequencies were calculated as a proportion of CD19+ cells (Fig. 1D). This analysis clearly
established anatomical differences in IgG BMem localization (P < 0.0001) and identified the
MedLN, lung, and d-NALT as sites of preferential concentration. The proportion of IgG BMem in
the CD19+ cell population was significantly higher in the MedLN than in all other sites except
the lung and d-NALT, and was significantly higher in the lung and d-NALT compared with the
spleen, inguinal lymph node (ILN), and blood (Fig. 1D, legend). The prominence of the o-NALT
and PP as sites of BMem localization (Fig. 1A) was less marked after standardizing the expression
of BMem frequencies. With this adjustment, frequencies in the o-NALT and PP were still
consistently higher than in the spleen and some lymph nodes, but differences were not
statistically significant. BMem frequencies did not correlate with participation of the tissue in the
immune response to influenza, as evidenced by significantly higher frequencies in the MedLN
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compared with the CLN (both responding sites), and similar frequencies in the CLN and nonresponding sites such as the PP and mesenteric lymph node (MesLN). The overall impression is
one of widespread IgG BMem dispersion modulated by local tissue factors.
The total number of IgG BMem in each anatomical location was calculated from the
frequency and cell yield (Fig. 1E). Because of its cellularity, the spleen was by far the major
repository with approximately 5,000 IgG BMem, representing close to two-thirds of the total IgG
BMem measured in the analysis.

Tissue distribution of influenza-specific IgA BMem
Influenza-specific IgA BMem frequencies differed depending on anatomical location (P =
0.0004) (Fig. 1F). Measurable IgA BMem frequencies were present on the majority of samplings
in the o-NALT, MedLN, lung, and blood. In all other locations examined, frequencies were
always below the level of sensitivity of the assay (frequency <1/105 cells). IgA BMem frequencies
in the o-NALT, MedLN, and lung were approximately one-tenth of the IgG BMem frequencies,
perhaps reflecting the overall IgA:IgG composition of the primary response to infection (Fig. 2A).
The presence of IgA BMem in the blood suggests continuous re-circulation, as was the case for
IgG BMem.

Kinetics of influenza-specific AFC and BMem generation and dispersion

61

To gain insights into the establishment of the dispersed state of B cell memory, we
determined influenza-specific ASC and BMem frequencies in selected sites at intervals after
infection (Fig. 2). A vigorous IgG ASC response accompanied by BMem production developed
first in the MedLN and later in the spleen (Fig. 2A). In contrast to the peak and decline in IgG
ASC frequencies in the MedLN and spleen, the pattern for IgG BMem was the quick
establishment and maintenance of the frequencies that were characteristic of these tissues in the
long-term (Fig. 2B). As early as day 7 after infection, the presence of circulating IgG BMem
indicated that BMem dispersion from sites of generation had commenced. Notably, IgG BMem were
detected in the lung as early as day 7 (<1/105 total cells) and had increased substantially in
numbers by day 9, raising the possibility of a functional significance of these cells during the
acute response. A limited analysis of IgA BMem on days 9 and 14 demonstrated circulating cells
and relatively high frequencies in the lung, emphasizing the lung as a site of rapid and
preferential BMem localization (Fig. 2C). ASC frequencies in the lung progressively increased
from 1-3 wk after infection and then plateaued, a kinetic pattern consistent with the immigration
of ASCs (and presumably also BMem) from other sites, rather than local synthesis. Although IgA
ASCs were consistently present in the blood from 1-3 wk after infection (5-10 IgA ASC/105
cells), circulating IgG ASCs were never detected, perhaps reflecting an influence of isotype
expression on the differentiation rate of activated B cells. IgG BMem were detected earlier and
established higher frequencies in the PP compared with the ILN, even though immune responses
to influenza do not occur in either site. The general pattern was for IgG BMem frequencies in all
tissues to increase and stabilize, with no evidence of contraction of the BMem pool during the
period of analysis.
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DISCUSSION
The state of B cell memory generated by influenza infection of the respiratory tract
provides profound and long-lasting resistance to reinfection with the homologous virus, as well
as varying levels of protection against non-homologous but serologically related strains. The
protection provided by pre-existing virus-specific Abs produced by ASCs in the upper and lower
respiratory tract and in the BM is well-recognized. However, much less attention has been given
to the virus-specific BMem pool, even though this is likely to be of considerable importance in
conferring long-term protection, especially if pre-existing Ab levels begin to fall. The present
analysis focuses on the virus-specific BMem population generated by primary influenza infection.
Our findings are consistent with the concept of widespread BMem dispersion to secondary
lymphoid tissues throughout the body. However, what also emerge are significant tissue-specific
influences on BMem localization. After adjusting for the proportion of CD19+ cells, the MedLN,
d-NALT, and lung stood out as sites of preferential IgG BMem localization. The high BMem
frequency in the MedLN is not simply a consequence of a vigorous B cell response and BMem
formation in this site, since the CLN also responds strongly to infection. Indeed, multiple site-tosite comparisons indicate that participation in the response to infection is not a determinant of the
IgG BMem frequency that is established. IgG BMem frequencies in the o-NALT and PP, although
significantly lower than in the MedLN, were still consistently higher than in the spleen and some
lymph nodes, suggesting additional complexity in the regulation of BMem localization. The set of
expressed homing molecules that direct BMem migration is not well-established and may vary
within the BMem population (Roy, Kim et al. 2002). Since naïve and BMem traffic through many of
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the same lymphoid tissues, there is likely to be considerable overlap in the homing molecules
that regulate the process (Rodrigo Mora and Von Andrian 2006). However, even subtle
differences between naïve and memory B cells in the expression levels of homing molecules may
be sufficient to bias BMem localization. For example, up-regulation of 4 7 on BMem (Roy, Kim
et al. 2002) may favor entry into the PP, o-NALT, and mucosa-associated lymph nodes, where
high endothelial venules (HEV) display relatively high levels of MadCAM-1, the 4 7 ligand
(Csencsits, Jutila et al. 1999). Our findings may also reflect tissue differences in the rate of
egress of lymphocytes. A key component of this process is receptor-mediated cell migration
along an increasing sphingosine-1-phosphate (S1P) concentration gradient between the lymphoid
tissue interior and adjacent blood or lymph (Cyster 2005). Inflammatory mediators released early
in immune responses stimulate local overproduction of S1P in lymphoid tissues, leading to
disruption of the S1P concentration gradient or down-regulation of cell receptors for S1P. The
result is a transient block in lymphocyte egress from lymphoid tissues. Thus, high BMem
frequencies in constitutively active lymphoid tissues like the PP and o-NALT may be a
consequence of both preferential entry and delayed egress.
Importantly, our studies demonstrate that a relatively high frequency of virus-specific
IgG BMem is established and maintained in the lung following influenza infection. This finding
emphasizes the complexity of the lung as a site for the localization of the cellular elements of
adaptive immunity. Previous studies have established that virus-specific ASCs and memory
CD4+ and CD8+ T cells persist in the lung long after influenza and other viruses that target the
respiratory tract have been cleared (Jones and Ada 1986; Hogan, Usherwood et al. 2001; Hogan,
Zhong et al. 2001; Ostler, Hussell et al. 2001). The kinetics of BMem (and ASC) movement into
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the lung resembled that previously reported for virus-specific CD4+ and CD8+ T cells (Cauley,
Cookenham et al. 2002; Roman, Miller et al. 2002; Lawrence, Ream et al. 2005). There is little
information on molecules specifically expressed by BMem that direct entry into the lung, but at
least initially the process is likely to resemble that for activated lymphocytes in general as they
exit the vasculature in response to local inflammation-associated changes (Kim 2004; Luster,
Alon et al. 2005). Up-regulation of 4 1 on BMem may be expected, since the 4 1/VCAM-1
adhesion pathway is a key element in lymphocyte trafficking into the inflamed lung (Feng,
Britton et al. 2000). The microanatomical location of BMem in the lung has not been identified,
but they may come to reside primarily in the relatively organized regions of lymphoid tissue that
form in lung within 10 days of infection (Moyron-Quiroz, Rangel-Moreno et al. 2004). This
lymphoid tissue, collectively referred to as induced bronchus-associated lymphoid tissue (BALT),
includes areas that resemble secondary lymphoid tissue with distinct B and T cell zones and
HEV. Lymphocyte homing to BALT, as well as to PP and peripheral lymph nodes, is highly
dependent on L-selectin and LFA-1 expression (Xu, Wagner et al. 2003). However, the BALT
homing pathway may rely particularly on 4 1/VCAM-1 interactions, since VCAM-1 is
expressed at much higher levels on BALT HEV than on HEV in other secondary lymphoid
tissues (Xu, Wagner et al. 2003). T cell studies indicate that lung lymphocytes are part of a recirculating pool (Moyron-Quiroz, Rangel-Moreno et al. 2006), moving via lymphatics through
draining lymph nodes to eventually reach the venous blood. A preferential lymphocyte
trafficking circuit from lung → draining lymph nodes → blood → lung has been proposed
(Zammit, Turner et al. 2006), and may underlay the high BMem frequencies that we consistently
observed in the MedLN. The IgG BMem frequency (as a proportion of CD19+ cells) was also
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relatively high in the d-NALT sample, which consisted of cells isolated from the thin tissue
lining the nasal cavity (o-NALT excluded). This result reflects the presence of a small number of
BMem in a tissue that contained few lymphocytes.
Influenza-specific IgG BMem frequencies in the BM were always below the level of
sensitivity of the assay (<1/105 cells), in contrast to the concentration of LLPCs in this site. Our
findings are consistent with other studies that reported the scarcity of BMem in the BM
(Bachmann, Kundig et al. 1994; Slifka, Antia et al. 1998). Interestingly, this contrasts with the
role of the BM as a significant reservoir of memory T cells (Marshall, Turner et al. 2001; Di
Rosa and Pabst 2005). Although distinct trafficking characteristics may contribute to the
difference between memory T and B cell frequencies in the BM (Mazo, Honczarenko et al.
2005), another factor may be BMem differentiation in the BM microenvironment to replenish the
LLPC population.
Only the o-NALT, MedLN, lung, and blood had measurable influenza-specific IgA BMem
frequencies when analyzed 8 wk or more after infection. This finding may simply reflect a
consistent ratio of IgG:IgA BMem (approximately 10:1) in all of the solid tissues sampled, since
this could result in IgA BMem frequencies below the level of assay sensitivity in all sites except
the o-NALT, MedLN, and lung. Alternatively, our data can be taken to reflect preferential IgA
BMem trafficking to the respiratory tract and associated lymphoid tissues. It is well established
that the expression of different sets of adhesion molecules and homing receptors by IgG- and
IgA-producing ASCs results in preferential trafficking to the BM and mucosal sites, respectively
(Cyster 2003). There is evidence for further compartmentalization of IgA ASC trafficking, with
preferential migration to either the small intestine or to other mucosal sites like the lung
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(McDermott and Bienenstock 1979). Further studies are required to firmly establish whether an
analogous situation applies to IgA BMem. Our analysis demonstrated a rapid increase in IgA BMem
frequency in the lung during the acute response, with maintenance of a lower frequency in the
long-term. In contrast, IgA BMem frequencies in the MedLN (presumably a key site of IgA BMem
formation) stabilized at higher frequencies after clearance of the virus. This may reflect the
lymphocyte trafficking pathway from lung to draining lymph nodes discussed above.
In our analysis of the MedLN and spleen, long-term BMem frequencies (per total cells)
were comparable to previous limiting dilution assay (LDA) determinations of memory CD4+ and
CD8+ T cell frequencies (Tripp, Sarawar et al. 1995; Topham, Tripp et al. 1996), although more
recent studies (for example, using tetramers) indicate that the CD8+ T cell frequencies may be
somewhat higher (Flynn, Belz et al. 1998; Hogan, Usherwood et al. 2001; Hogan, Zhong et al.
2001). A more dramatic difference exists in the lung; at least when comparing memory B and
CD8+ T cell frequencies (and numbers). During the memory phase after a primary infection,
influenza-specific CD8+ T cell numbers in the lung may exceed our estimate of BMem numbers by
up to 100-fold (Hogan, Usherwood et al. 2001; Lawrence, Ream et al. 2005). This difference
may be much less marked for memory CD4+ T cells, which decrease in frequency in the lung
much more rapidly than do CD8+ T cells after viral clearance (Cauley, Cookenham et al. 2002).
A stable population of approximately 30,000 influenza-specific ASCs was maintained in the lung
following infection. These cells, which can be considered the effector form of BMem, are
numerically more comparable to the memory CD8+ T cell population in the lung. It is not known
whether our LDA strategy underestimates influenza-specific BMem frequencies, as was shown to
be the case for LDA analysis of CD8+ T cell frequencies prior to the introduction of tetramers.
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However, at present, our approach may be the best option for enumerating a BMem population
representing specificities for multiple, often poorly defined epitopes on different molecules.
In summary, the current report provides the most comprehensive picture currently
available of the dispersed virus-specific BMem pool generated by primary influenza infection.
Perhaps primarily, our findings focus attention on the lung as a complex repository of B and T
cell memory that may contribute substantially to resistance to respiratory infections. The concept
of effector lymphoid tissue (ELT) has been introduced to describe the stable accumulations of
functionally significant memory T cells that are established in non-lymphoid tissues as a
consequence of infection (van Panhuys, Perret et al. 2005). Our studies demonstrate that BMem
(as well as ASCs) should be recognized as components of the ELT that develops in the lung
following influenza infection. Future studies are required to relate BMem numbers, location, and
isotype expression to protective immunity and may have important implications for vaccine
development.
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Figure 1. Quantitative analysis of anatomically dispersed influenza-specific BMem and ASCs.
Mice were sampled 8-12 wk after i.n. influenza infection. Abbreviations: o-NLT, organized
nasal-associated lymphoid tissue; CLN, cervical lymph node; Med, mediastinal lymph node; Spl,
spleen; ILN, inguinal lymph node; PP, Peyer’s patches; Mes, mesenteric lymph node; BM, bone
marrow; d-NLT, diffuse nasal-associated lymphoid tissue. (A) IgG BMem frequencies expressed
as a proportion of total cells. BMem frequencies (A, F) were determined by LDA based on in vitro
stimulation of BMem to generate ASCs. Formation of IgG and IgA ASCs were taken to reflect
precursor IgG and IgA BMem respectively. P < 0.0001 for frequency differences among
anatomical locations. ao-NLT vs ILN, d-NLT, and blood (P < 0.001), and vs CLN, spleen, and
Mes (P < 0.01). bMed vs CLN, Spl, ILN, Mes, d-NLT, lung, and blood (P < 0.001). cPP vs ILN,
d-NLT, and blood (P < 0.05). Data are mean + s.e.m. (n = 4-6 for PP, Mes, BM, d-NLT, and
blood; otherwise n = 8-12). (B) IgG and IgA ASCs were enumerated by direct ex vivo ELISPOT
assay and are expressed as a proportion of total cells. Data are mean + s.e.m. (n = 5-12). (C)
Percentages of B cells (CD19+) and T cells (CD3+) were determined by flow cytometry. Data are
mean + s.e.m. (n = 5-12). (D) IgG BMem frequencies shown in A expressed as a proportion of
CD19+ cells. Data are mean + s.e.m. P < 0.0001 for frequency differences among anatomical
locations. aMed vs CLN, Spl, ILN, and blood (P < 0.001), vs o-NLT and Mes (P < 0.01), and vs
PP (P < 0.05). bd-NLT vs ILN and blood (P < 0.01), and vs Spl (P < 0.05). cLung vs vs ILN and
blood (P < 0.01), and vs Spl (P < 0.05). (E) Total IgG BMem were calculated from the frequency
(shown in A) and cell yield. Data are mean + s.e.m. (F) IgA BMem frequencies expressed as a
proportion of CD19+ cells. Only tissues that had measurable IgA BMem frequencies on at least
one occasion are shown. The median of each group is indicated by a line. Frequencies were
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below the level of assay sensitivity in the following tissues (n = 3-5): CLN, Spl, ILN, PP, Mes,
and BM. P = 0.0004 for frequency differences among all anatomical locations analyzed. IgA
BMem frequencies were not significantly different in pairwise comparisons of anatomical
locations.
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Figure 2. Kinetic analysis of influenza-specific ASC and BMem generation and dispersion. Mice
were sampled at intervals after i.n. influenza infection. Data for days 56-84 from the analysis
shown in Fig. 1 are included for comparison. Abbreviations: MedLN, mediastinal lymph node;
ILN, inguinal lymph node; PP, Peyer’s patches. (A) IgG and IgA ASC frequencies in the MedLN,
spleen, and lung were enumerated by direct ex vivo ELISPOT assay and are expressed as a
proportion of total cells. Data are mean + s.e.m. (n = 3-7 for days 7-28). (B) IgG BMem
frequencies in the MedLN, spleen, lung, ILN, PP, and blood expressed as a proportion of CD19+
cells. Frequencies were determined by LDA based on in vitro stimulation of BMem to generate
ASCs. Formation of IgG ASCs was taken to reflect precursor IgG BMem. Data are mean + s.e.m.
(n = 3 for days 7-28). *The IgG BMem frequency in the responding MedLN on day 7 was >1/105
cells, but could not be accurately measured by LDA. (C) IgA BMem frequencies in the MedLN,
spleen, lung, ILN, PP, and blood expressed as a proportion of CD19+ cells. Frequencies were
determined as for B, with formation of IgA ASCs taken to reflect precursor IgA BMem. Data are
mean + range (n = 2).
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Chapter 4
Quantitative analysis of influenza virus-specific B cell
memory generated by different routes of inactivated
virus vaccination
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Abstract
The humoral response to inactivated viral vaccines generates a state of B cell memory in
the form of Ab-secreting cells (ASCs) and memory B cells (BMem) that determines protective
efficacy. Although the activation of BMem by recall Ag contributes substantially to protection, the
population characteristics of BMem generated by vaccination has received little attention. Here,
we consider both ASC and BMem populations in a quantitative analysis of virus-specific B cell
memory generated by intramuscular or intranasal vaccination of mice with inactivated influenza
virus. The memory phase after both forms of vaccination was characterized by localization of
ASCs in the bone marrow and dispersion of BMem to organized lymphoid tissues. Other features
of B cell memory reflected the form of vaccination: the stronger IgG response to intramuscular
vaccination correlated with larger numbers of IgG ASCs in the bone marrow and IgG BMem; IgA
production was only prominent in the response to intranasal vaccination and was associated with
IgA ASC localization in the lung and IgA BMem formation. Nevertheless, the BMem pools
generated by both forms of vaccination were comparably effective in responding to viral
challenge. Notably, few IgG ASCs or BMem localized in the lung after intramuscular vaccination,
a marked contrast with the preferential localization of ASCs and BMem in the lung following
influenza pneumonia. Our analysis links the route of Ag administration to characteristics of B
cell memory that may relate to protective immunity, and emphasizes the potentially suboptimal
state of B cell memory in the lung after intramuscular vaccination.
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Introduction
Characteristics of the B cell response, and particularly the nature of long-term B cell
memory, are key determinants of the protective capacity of many vaccines (Subbarao and Joseph
2007). Ab-secreting cells (ASCs)3 generated during B cell responses and persisting into the
memory phase provide one component of B cell memory (McHeyzer-Williams and McHeyzerWilliams 2005). Long-lived ASCs are primarily recognized as a bone marrow (BM)-resident
population that maintains circulating Ab levels (Hyland, Sangster et al. 1994; Slifka, Antia et al.
1998). ASC populations may also be established and maintained at mucosal surfaces, typically
following mucosal immunization (Jones and Ada 1986; Liang, Hyland et al. 2001). A second
cellular component of B cell memory is formed by memory B cells (BMem) which are generated
in parallel with ASCs during B cell responses (Anderson, Tomayko et al. 2006). BMem are longlived, non-ASCs that, upon activation, divide and differentiate into ASCs and mediate the rapid,
vigorous, and high affinity secondary Ab response (Ahmed and Gray 1996). The contribution of
the BMem response to protection is particularly important when pre-existing ASC numbers (and
thus Ab levels) begin to wane.
As a result of recent studies, a more complete picture of the BMem pool generated by viral
infection is emerging. It is now well-established that BMem generated during the acute response
circulate and disperse to secondary lymphoid tissues throughout the body (Bachmann, Kundig et
al. 1994; Vanitha, Joo et al. 2007; Joo, He et al. 2008). In addition, some non-lymphoid organs
that are a target of infection may become significant repositories of BMem, perhaps reflecting de
novo lymphoid tissue formation in these locations (Carragher, Rangel-Moreno et al. 2008). An
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analysis of B cell memory induced by influenza infection identified the lung as a site where BMem
(as well as ASCs) preferentially localize (Joo, He et al. 2008).
In contrast to the situation following infection, little information is available on the nature
of BMem populations generated by vaccination. These cells are likely to be especially important
when the protective efficacy of a vaccine is largely determined by its ability to elicit a humoral
response. Such vaccines include the most widely used form of influenza vaccine, an inactivated
split virus preparation that is administered i.m (Gerdil 2003). Generally, influenza-specific
circulating Ab levels induced by this vaccine have declined by 6 mo after immunization (Powers,
Smith et al. 1995; Kunzel, Glathe et al. 1996), but a longer-lasting BMem pool remains to respond
to recall Ag and enhance resistance to infection (Wrammert, Smith et al. 2008). Here we report a
comprehensive quantitative analysis of the state of virus-specific B cell memory generated by
vaccination with inactivated influenza virus. Our analysis considers the BMem and ASC
populations resulting from i.m. or intranasal (i.n.) Ag administration. We show that parameters
of B cell memory that may relate to the level of protective immunity are influenced by the route
of immunization. In particular, our analysis emphasizes the marked difference between B cell
memory in the lung generated by i.m. vaccination and the situation following influenza
pneumonia.
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Materials and methods
Mice and immunizations
C57BL/6J mice purchased from The Jackson Laboratory (Bar Harbor, ME) were housed
under specific pathogen-free conditions. Female mice were used in all experiments and were
immunized at 8-12 weeks of age. The Animal Care and Use Committee of the University of
Tennessee approved all animal procedures.
Preparations of sucrose gradient-purified influenza virus A/HKx31 (H3N2) inactivated by
treatment with formaldehyde or -propiolactone were purchased from Charles River
(Wilmington, MA). Results were not affected by the method of inactivation. A stock of
infectious influenza virus HKx31 was grown and titrated in the allantoic cavity of embryonated
hen’s eggs. Mice were anesthetized with Avertin (2,2,2-tribromoethanol) given i.p. before all
immunizations. For i.m. vaccination, a total dose of 20 g of inactivated virus was given in two
injections, each of 10 g (50 l in PBS), into the tibialis anterior muscle of each leg. A plastic
sleeve over the needle controlled the depth of injection. The dose of inactivated virus for i.n.
vaccination was 30 g (30 l in PBS). Vaccinated mice were challenged i.n. with 106.8 50% egg
infectious doses of influenza virus (30 l in PBS).

Tissue sampling and treatment
Anesthetized mice were exsanguinated via the retro-orbital plexus before tissue sampling.
Tissues were processed to generate single-cell suspensions in IMDM (Invitrogen, Carlsbad, CA)
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containing L-glutamine (2 mM), sodium pyruvate (1 mM), penicillin (100 IU/ml), streptomycin
(100 g/ml), gentamicin (10 g/ml), and 5 x 10-5 M -mercaptoethanol (designated B cell
medium), and supplemented with 10% FBS. Lymph nodes and spleen were collected and gently
disrupted between the frosted ends of microscope slides. BM cell suspensions were obtained by
flushing the femurs and tibiae. RBCs were removed from the spleen and BM preparations by
ammonium chloride lysis. The organized nasal-associated lymphoid tissue was collected
attached to the palate (Asanuma, Thompson et al. 1997) and cells were released by teasing.
Lungs were finely minced and incubated for 1 h at 37°C in B cell medium containing 10% FBS
and 4 mg/ml collagenase type II (Worthington, Lakewood, NJ). Cells pelleted from the lung
digest were resuspended in 40% isotonic Percoll and layered over 75% isotonic Percoll. After
centrifugation at 600g for 20 min at 25°C, cells at the interface were collected and washed. PP
were dissected from the small intestine and washed, and cells were released by digestion with 2
mg/ml collagenase type I (Worthington) for 30 min at 37°C. Blood was collected into heparin
sodium (1,000 USP Units/ml, Abraxis, Schaumburg, IL), diluted in an equal volume of HBSS
containing 0.1% BSA, layered over Lympholyte-Mammal (Cedarlane, Burlington, NC) and
centrifuged at 800g for 20 min at 25°C. Cells at the interface were then collected and washed.
Lungs to be titrated for infectious virus were homogenized in 1 ml HBSS containing 0.1%
BSA. Homogenates were clarified by centrifugation, and supernatants were stored at -80°C.
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Virus titration
Viral titers in lung homogenates were determined by 50% tissue culture infective dose
assay using Madin Darby canine kidney cells grown in MEM containing L-glutamine (2 mM),
penicillin (100 IU/ml), streptomycin (100 g/ml), and 5% FBS. Confluent cell monolayers in 96well tissue culture plates were washed once with serum-free MEM immediately before the
addition of viral inocula. Serial 10-fold dilutions of lung homogenates were prepared in MEM
containing 0.3% BSA and 1 g/ml L-(toslyamido 2-phenyl) ethyl chloromethyl ketone-treated
trypsin (Worthington), and 0.2 ml volumes were added to the appropriate wells. After 2 days
incubation at 37°C with 5% CO2, wells positive for virus growth were identified by the presence
of hemagglutinating activity.

ELISPOT assay
Influenza-specific ASCs were enumerated by ELISPOT assay as previously described (Li,
Vanitha et al. 2006). Briefly, plates were coated with purified influenza HKx31 (Charles River)
and single cell suspensions were plated and incubated. Alkaline phosphatase-conjugated goat
anti-mouse Abs with specificity for Ig isotypes or IgG (Southern Biotechnology, Birmingham,
AL) were used in combination with the substrate 5-bromo-4-chloro-3-indolyl phosphate (Sigma,
St. Louis, MO) to generate spots.
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ELISA
Influenza-specific Ab levels in sera were determined by ELISA (Sangster, Topham et al.
2000) using plates coated with purified, detergent-disrupted influenza HKx31 (0.5 g/well).
Briefly, serial 3-fold serum dilutions were added to the plates, and bound Ab was detected with
ALP-conjugated goat anti-mouse IgG (Southern Biotechnology) and p-nitrophenyl phosphate
substrate. Ab concentrations in arbitrary units were calculated from standard curves constructed
using goat anti-mouse IgG capture Ab and a purified mouse Ig standard (Southern
Biotechnology).

Memory B cell assay
Influenza-specific BMem frequencies were determined by a previously described limiting
dilution assay based on in vitro stimulation of BMem to differentiate into ASCs (Li, Vanitha et al.
2006). Briefly, two-fold dilutions of cells from immune mice were incubated in 96-well tissue
culture plates (routinely 12 wells per dilution starting with 105 cells per well), together with 106
irradiated (3000 rad) syngeneic naïve spleen cell feeders plus -propiolactone-inactivated
HKx31. Plates were incubated for 4 days at 37°C in a humidified atmosphere containing 5% CO2.
After incubation, cells in each well were washed thoroughly and transferred to ELISPOT plates
for the enumeration of influenza-specific IgG or IgA ASCs. Pre-existing virus-specific ASC
numbers in immune cell populations at the time of sampling were determined by direct ex vivo
ELISPOT assay. After in vitro BMem activation and ELISPOT analysis, individual wells were
scored positive for virus-specific BMem if progeny ASC numbers were greater than twice the
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mean pre-existing ASC. The virus-specific BMem frequency was calculated from the number of
negative wells per cell dilution by extrapolation to the dilution that gave 37% negative wells
(Topham and Doherty 1998). BMem frequencies of less than one per 105 input cells could not be
accurately determined. Virus-specific IgG and IgA BMem were defined as cells that generated IgG
and IgA ASCs, respectively, after in vitro stimulation (Okumura, Julius et al. 1976; Coffman and
Cohn 1977). At the time of sampling, cell populations were characterized by flow cytometry
using FITC-conjugated anti-CD3 (145-2C11) and PE-conjugated anti-CD19 (1D3) mAbs (BD
Biosciences, San Diego, CA) as staining reagents. Spleens were processed individually;
otherwise tissues were generally pooled from 2-5 mice to generate sufficient cells for analysis.
To accomodate tissue differences in the proportion of CD19+ B cells, the population that
includes the BMem (Bell and Gray 2003; Blink, Light et al. 2005; Li, Vanitha et al. 2006), BMem
frequencies are expressed for CD19+ cells.

Statistical analysis
Mean BMem values were analyzed using one-way ANOVA and the Tukey post test for
multiple comparisons. The nonparametric Kruskal-Wallis test and Dunn’s post test were used as
required to accommodate BMem values below the limit of assay sensitivity. Other comparisons of
group means were performed using the nonparametric Mann-Whitney U test for unpaired
samples. Tests were performed using GraphPad software (SanDiego, CA). Values of P < 0.05
were considered statistically significant.
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Results
Influenza-specific Ab responses to intramuscular and intranasal administration of
inactivated virus
Initial experiments evaluated the magnitude and quality of the influenza-specific ASC
response following two routes of administration of inactivated virus. The i.m. route was used to
model human vaccination with inactivated influenza virus, and the i.n. route was included to
determine whether mucosal Ag administration influenced parameters of B cell memory.
Influenza-specific ASCs in different tissues were enumerated by ELISPOT assay. Responses in
the draining lymph nodes and the spleen after i.m. vaccination were characterized by early IgM
production, followed by increased numbers of cells producing IgG2c and, to a lesser degree,
IgG2b (Fig 1). IgG production in responding lymphoid tissues was weaker following i.n.
compared with i.m. vaccination (Fig 2), likely reflecting some loss of effective Ag following
mucosal administration. However, the response to i.n. vaccination included a substantial IgA
component (see CLN and spleen), which was essentially absent in the response to i.m.
vaccination.
Responses in draining lymph nodes and spleen had substantially waned by 3 wk after
vaccination by both routes, but ASC populations were established in the BM and maintained into
the memory phase (Fig 3A and D). BM ASC populations reflected the isotype composition of the
acute response, with IgG or IgA ASCs predominating after i.m. or i.n. vaccination, respectively.
Higher IgG ASC numbers in the BM and serum IgG levels following i.m. compared with i.n.
vaccination were consistent with a generally stronger acute IgG response (Fig 3C and F).
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IgA ASCs generated by i.n. vaccination localized in the lung as well as in the BM (Fig
3D and E). In contrast, very few IgG ASCs were detected in the lung after either route of
vaccination (Fig 3B and E), consistent with the notion of differential ASC trafficking patterns
related to isotype expression.

Influenza-specific BMem generated by intramuscular and intranasal vaccination with
inactivated virus
Influenza-specific BMem frequencies in a range of anatomical locations were measured by
limiting dilution analysis 8-12 wk after vaccination, a time when fully dispersed and stable BMem
populations would be expected. To standardize site-to-site comparisons, BMem frequencies were
calculated as a proportion of CD19+ cells, the cell population that contained the influenzaspecific BMem in this analysis (Joo, He et al. 2008). IgG BMem generated by i.m. vaccination
dispersed widely to all secondary lymphoid tissues sampled (Fig 4A). Significant variation
among mean IgG BMem frequencies in these tissues (p < 0.02) indicated local influences on
trafficking. Participation of the tissue in the immune response to vaccination did not correlate
with higher BMem frequencies. IgG BMem were consistently detected in the blood, indicating a
process of continuous recirculation. Lymphocyte populations isolated from the lung after i.m.
vaccination occasionally contained influenza-specific IgG BMem, but frequencies were generally
below the limit of sensitivity of the assay, a situation that contrasted with preferential
localization of BMem in the lung after influenza pneumonia (Joo, He et al. 2008).

85

IgG BMem frequencies were markedly lower after i.n. compared with i.m. vaccination (Fig
4B), reflecting the relatively weaker acute IgG response. The presence of IgG BMem in all of the
sampled sites was evident by the presence of influenza-specific IgG ASC after in vitro
stimulation, emphasizing broad dispersion of these cells and continuous recirculation. However,
only the o-NALT, MLN, and PP consistently had BMem frequencies above the limit of assay
sensitivity after i.n. vaccination. Significant variation among mean IgG BMem frequencies (p <
0.001) indicated a non-uniform pattern of dispersion to organized lymphoid tissues. IgG BMem
were infrequent in the lung, indicating that preferential BMem localization in this tissue (Joo, He
et al. 2008) is not simply a consequence of i.n. Ag administration.
A limited analysis of the CLN, MLN, o-NALT, and lung indicated a higher frequency of
IgA BMem after i.n. compared with i.m. vaccination, consistent with the isotype composition of
the primary response. Only cell populations (particularly o-NALT cells) from i.n. vaccinated
mice gave rise to influenza-specific IgA ASCs during in vitro stimulation of limiting dilution
cultures, indicating the presence of precursor IgA BMem (data not shown). However, IgA BMem
frequencies were less than 1 in 105 CD19+ cells and could not be accurately determined.
To further evaluate BMem populations generated by inactivated virus vaccination, mice
primed by the i.m. or i.n. routes were challenged i.n. with live homologous virus. The Ag load
following challenge may have differed in the two groups of primed mice because of differences
in the levels of pre-existing local and systemic Abs (Fig 3). Nevertheless, the route of
vaccination markedly influenced the isotype composition of the secondary response. The
secondary response in the CLN of i.n. primed mice had a strong IgA component (Fig 5),
consistent with a higher proportion of IgA BMem. There was a small IgA component in the
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secondary response of i.m. primed mice, even though IgA BMem in these mice were not detected
by limiting dilution analysis. Both i.m. and i.n. priming provided a high level of protection. At
the time of sampling (day 5), infectious virus titers in the lungs of both groups of primed mice
were not significantly different, and were more than 100-fold lower than in the lungs of
unprimed mice (data not shown).

Lung localization of B cell memory is poorly induced by intramuscular vaccination
A recent study of virus-specific B cell memory generated by influenza pneumonia
identified the lung as a site of preferential localization of ASCs and BMem (Joo, He et al. 2008).
In contrast, the current analysis of the response to a single i.m. vaccination demonstrated
systemic B cell memory, but very few ASCs or BMem in the lung (Figs 3 and 4). To test for an
effect of response magnitude, the state of B cell memory in the lung was evaluated after priming
and boosting with inactivated virus given i.m. Effective expansion of influenza-specific B cell
memory by boosting was indicated by a vigorous secondary B cell response in draining lymph
nodes and a significant increase in IgG ASC numbers in the BM and serum IgG levels (Fig 6AD). However, there was no significant change in the minimal numbers of ASCs or BMem present
in the lung (Fig 6E and F). Surprisingly, IgG BMem frequencies in the spleen were not obviously
increased by boosting, raising the possibility that BMem expansion does not parallel ASC
formation. Overall, the impression is that factors other than response magnitude regulate
localization of B cell memory in the lung.
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Discussion
The state of B cell memory in the form of ASCs and BMem is the critical determinant of
the protective efficacy of inactivated viral vaccines. Our analysis provides a comprehensive
quantitative picture of the state of virus-specific B cell memory generated by i.m. and i.n.
vaccination with inactivated influenza virus. The localization and maintenance of ASC
populations in the BM (Hyland, Sangster et al. 1994; Slifka, Antia et al. 1998) and the
continuous circulation and broad dispersion of BMem to organized lymphoid tissues (Bachmann,
Kundig et al. 1994; Vanitha, Joo et al. 2007; Joo, He et al. 2008) are established features of B
cell memory that were common to both forms of vaccination. However, other features that may
impact protective efficacy depended on the route of Ag administration.
The i.m. administration of inactivated virus is widely used for human influenza
vaccination (Nichol and Treanor 2006). The levels of circulating IgG induced by this strategy
correlate with resistance to influenza in humans (Cox, Brokstad et al. 2004), but Ab levels
typically begin to fall after vaccination (Powers, Smith et al. 1995; Kunzel, Glathe et al. 1996).
As this happens, BMem and the rapid recall response they mediate are likely to become
increasingly important determinants of protection (Wrammert, Smith et al. 2008). In our analysis,
acute IgG production was appreciably stronger following i.m. compared with i.n. vaccination,
probably simply reflecting differences in the efficiency of Ag delivery to the immune system.
The stronger IgG response correlated with a larger IgG ASC population in the BM, higher
circulating IgG levels, and a quantitatively greater IgG BMem pool. Our analysis establishes that
IgG BMem generated by i.m. vaccination would have rapid access to Ag entering the body via any
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route, as reflected in the vigorous secondary Ab response following i.n. influenza challenge. In
particular, localization of BMem in organized lymphoid tissues associated with the respiratory
tract would ensure prompt activation in the event of influenza infection. Furthermore, the
presence of BMem in the circulation suggests a mobile population that continuously traffics
through lymphoid tissues surveying for cognate Ag.
As would be expected in a comparison of mucosal and non-mucosal Ag administration,
IgA production was prominent in the response to i.n. but not to i.m. vaccination (Neutra and
Kozlowski 2006), and this was reflected in differences in the state of B cell memory. Only i.n.
vaccination resulted in a durable IgA ASC population in the lung, thus providing a potentially
valuable, broadly protective barrier to infection at the site of virus encounter. In addition, the
BMem population generated by i.n. vaccination included a greater number of IgA BMem. A
practical benefit of this is suggested by the substantial IgA component of the secondary B cell
response to i.n. challenge of i.n. vaccinated compared with i.m. vaccinated mice (Fig. 5). Rapid
BMem activation is undoubtedly a valuable protective response, regardless of the Ab isotype
expression profile. However, the presence of IgA BMem may confer an additional advantage,
since IgA ASCs generated by IgA BMem activation would rapidly localize to sites of viral
replication in the upper respiratory tract (Liang, Hyland et al. 2001; Sangster, Riberdy et al.
2003). Interestingly, the secondary response to i.n. challenge of i.m. vaccinated mice included an
IgA component (Fig. 5), perhaps reflecting the activation of small numbers of IgA BMem.
Analysis of lymphoid tissue populations after i.m. vaccination did not identify IgA BMem, but this
may reflect numbers below the limit of assay sensitivity. It may be noteworthy that IgA ASCs
were not completely absent from the response to i.m. vaccination. The presence of IgA ASCs in
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the BM after i.m. vaccination (Fig. 3A) suggests a germinal center origin (Smith, Light et al.
1997) and it is therefore likely that some IgA BMem were generated in parallel. Alternatively, IgG
BMem may retain the potential to switch to IgA expression when activated in an IgA-inductive
environment.
The state of B cell memory in the lung following influenza infection is profoundly
different from that following i.m. vaccination. Recent analysis of a mouse model of influenza
pneumonia demonstrated preferential localization of IgG- and IgA-expressing ASCs and BMem in
the lung (Joo, He et al. 2008). In contrast, the current analysis detected few virus-specific ASCs
or BMem in the lung after i.m. vaccination, and the situation was unchanged after a second i.m.
immunization to expand B cell memory (Fig. 6). Data presented in Fig. 7 emphasize the contrast
in ASC and BMem localization after influenza infection and i.m. vaccination: infection resulted in
approximately 10-fold higher ASC frequencies in the lung than in the BM, and approximately 3fold higher IgG BMem frequencies in the lung than in the spleen; i.m. vaccination resulted in
essentially the opposite ratios with preferential localization of ASCs in the BM and BMem in the
spleen. Apparently, ASC and BMem trafficking to the lung is modulated by local environmental
factors associated with influenza infection. Factors associated with inflammation are likely to
play a role, but mechanisms may differ depending on cell type and Ab isotype expression.
The stable population of approximately 30,000 virus-specific ASCs established in a
mouse lung after influenza infection consists of similar numbers of IgA and IgG ASCs (Joo, He
et al. 2008). Molecular interactions that regulate ASC homing to the lung are not fully
understood. IgA ASCs are programmed to migrate to mucosal sites by the expression of
chemokine receptors responsive to ligands constitutively produced at mucosal locations. The
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expression of different chemokine receptors may direct IgA ASC trafficking to specific mucosal
compartments, such as the lung or the small intestine (Mora and von Andrian 2009).
Interestingly, chemokine receptor expression may be influenced by the site of cell activation,
such that IgA ASCs formed in lymph nodes draining the respiratory tract are programmed to
home to the lung (McDermott and Bienenstock 1979). The regulation of IgG ASC trafficking is
somewhat different (Cyster 2003). IgG ASCs express CXCR4 and generally localize in the BM
in response to the production of CXCL12, the CXCR4 ligand. However, at least a proportion of
IgG ASCs also express CXCR3 and are responsive to chemokines produced at sites of
inflammation (Hauser, Debes et al. 2002). CXCL12 production may be upregulated at
inflammatory sites (Nanki, Hayashida et al. 2000), and circulating inflammation-associated
molecules decrease CXCL12 levels in the BM (Ueda, Yang et al. 2004). The potential for IgG
ASCs to bind to activated endothelium and enter sites of inflammation is enhanced by expression
of P-selectin glycoprotein ligand-1 and 4 1 (Underhill, Minges Wols et al. 2002). Overall, the
impression is that IgA ASCs, and perhaps specifically those generated in lymph nodes draining
the respiratory tract, are pre-programmed to home to the lung, whereas IgG ASC trafficking is
modulated by ongoing inflammation, as would occur during influenza infection. Our
observations are consistent with this scenario. Lung inflammation is unlikely to be a
consequence of the i.m. (in particular) or i.n. administration of inactivated virus. Thus, IgG ASCs
generated by i.m. vaccination localized in the BM but not in the lung, and lung localization of
ASCs after i.n. vaccination was essentially limited to IgA ASCs. Little information is available
on molecules expressed by BMem that direct entry into the lung. IgG BMem were readily detectable
in diverse lymphoid tissues after i.m. vaccination but, in contrast to the situation after influenza
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infection, few localized in the lung. Inflammation in the lung may also be a prerequisite for at
least IgG BMem localization. A consequence of influenza infection is formation in the lung of
regions of relatively organized lymphoid tissue referred to as inducible bronchus-associated
lymphoid tissue (iBALT) (Moyron-Quiroz, Rangel-Moreno et al. 2004). The iBALT has
characteristics of secondary lymphoid tissue and may provide a microenvironment for the
concentration of BMem (and perhaps ASCs), but this has not been established.
Our analysis of the state of B cell memory generated by i.m. vaccination emphasizes a
number of features that provide valuable protection against influenza. It is well-recognized that
this vaccination strategy effectively generates circulating virus-specific IgG that is likely
maintained by BM ASCs. Ready access of circulating IgG to sites of influenza replication,
especially in the lower respiratory tract, is likely to result from transudation, and this would be
enhanced by local inflammation (Persson, Erjefalt et al. 1998). Importantly, our analysis
establishes that the BMem pool generated by i.m. vaccination has characteristics that ensure a
potent secondary B cell response to influenza infection. However, our analysis also raises the
possibility that the state of B cell memory established in the lung after i.m. vaccination is
suboptimal. In particular, this is suggested by a consideration of the situation following influenza
infection. What remains to be determined is the protective advantage of lung localization of the
cellular elements of B cell memory. Certainly, a case can be made for the value of virus-specific
ASCs in the lung. It is well-established that IgA produced by submucosal ASCs is transcytosed
across epithelial cells to provide a barrier to infection at the luminal surface. IgG produced by
ASCs in the lung parenchyma may supplement this barrier, perhaps after transcytosis across
respiratory tract epithelial cells by a process involving FcRn (Spiekermann, Finn et al. 2002).
92

The advantage of a lung-localized BMem population is less clear, although these cells are wellpositioned to respond rapidly to influenza infection. Future studies aimed at understanding the
relationship between B cell memory in its various forms and protective immunity will be
important for the optimization of vaccination strategies.

93

APPENDIX

94

A

300

ASC/5 x 10 5

250

IgM
IgG1
IgG2b
IgG2c
IgG3
IgA

Popliteal LN

200
150
100
50
0

B

7

9

12

21

7

9

12

21

7

9

12

21

7

9

12

21

300
250

ASC/5 x 10 5

5

Inguinal LN

200
150
100
50
0

C

250

ASC/5 x 10 5

5

300

Iliac LN

200
150
100
50
0

D

5

300

Spleen

ASC/5 x 10 5

250
200
150
100
50
0

5

Days after immunization

95

Figure 1. The acute influenza-specific ASC response to i.m. vaccination. The kinetics of virusspecific ASC responses in the popliteal lymph node (A), inguinal lymph node (B), iliac lymph
node (C), and spleen (D) were determined for mice vaccinated i.m. with inactivated influenza
virus. The ELISPOT assay was used to enumerate influenza-specific ASCs in cell suspensions
from individual mice. Results are expressed as the number of ASC/5 x 105 nucleated cells. Data
are mean + SE (n = 3-5).
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Results are expressed as the number of ASC/5 x 105 nucleated cells. Data are mean + SE (n = 37).
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analysis based on in vitro stimulation of BMem to generate ASCs and are expressed as a
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